0001460702 2026-01-01 2026-03-31 0001460702 2026-05-11 0001460702 2026-03-31 0001460702 2025-12-31 0001460702 us-gaap:RelatedPartyMember 2026-03-31 0001460702 us-gaap:RelatedPartyMember 2025-12-31 0001460702 AIXC:SeriesA2PreferredStockMember 2026-03-31 0001460702 AIXC:SeriesA2PreferredStockMember 2025-12-31 0001460702 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001460702 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001460702 2025-01-01 2025-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001460702 us-gaap:CommonStockMember 2025-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001460702 us-gaap:RetainedEarningsMember 2025-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001460702 us-gaap:CommonStockMember 2024-12-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001460702 us-gaap:RetainedEarningsMember 2024-12-31 0001460702 2024-12-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001460702 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001460702 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001460702 us-gaap:CommonStockMember 2026-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001460702 us-gaap:RetainedEarningsMember 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001460702 us-gaap:CommonStockMember 2025-03-31 0001460702 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001460702 us-gaap:RetainedEarningsMember 2025-03-31 0001460702 2025-03-31 0001460702 AIXC:NanoSynexLtdMember 2022-12-31 0001460702 AIXC:SubscriptionAgreementMember 2025-09-01 2025-09-30 0001460702 AIXC:SeriesBConvertiblePreferredStockMember AIXC:SubscriptionAgreementMember 2025-09-30 0001460702 AIXC:SeriesBConvertiblePreferredStockMember AIXC:SubscriptionAgreementMember 2025-09-01 2025-09-30 0001460702 2025-01-01 2025-12-31 0001460702 AIXC:CardanoADAMember 2026-03-31 0001460702 AIXC:NativeBNBMember 2026-03-31 0001460702 AIXC:BitcoinMember 2026-03-31 0001460702 AIXC:EthereumMember 2026-03-31 0001460702 AIXC:ChainLinkMember 2026-03-31 0001460702 AIXC:SolanaMember 2026-03-31 0001460702 AIXC:TronMember 2026-03-31 0001460702 AIXC:USDTetherMember 2026-03-31 0001460702 AIXC:RippleMember 2026-03-31 0001460702 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001460702 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001460702 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001460702 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001460702 AIXC:FaradayFutureIntelligentElectricIncMember 2026-02-01 2026-02-28 0001460702

us-gaap:OtherIncomeMember

2026-01-01 2026-03-31 0001460702

us-gaap:OtherIncomeMember

2025-01-01 2025-03-31 0001460702 AIXC:MarizymeNotesMember 2026-01-01 2026-03-31 0001460702 AIXC:MarizymeNotesMember 2026-03-31 0001460702 us-gaap:CommonStockMember 2024-11-20 0001460702 2024-11-20 0001460702 AIXC:PreFundedWarrantsMember AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:PreFundedWarrantsMember AIXC:SeriesA2ConvertiblePreferredStockMember 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2026-01-01 2026-03-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2026-03-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2026-03-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2026-03-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-01-01 2025-03-31 0001460702 AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-03-31 0001460702 srt:MinimumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-03-31 0001460702 srt:MaximumMember AIXC:SeriesCWarrantsMember AIXC:CommonStockWarrantsMember 2025-03-31 0001460702 AIXC:PreFundedWarrantsMember 2026-03-31 0001460702 AIXC:PreFundedWarrantsMember 2025-03-31 0001460702 us-gaap:FairValueInputsLevel1Member 2026-01-01 2026-03-31 0001460702 us-gaap:FairValueInputsLevel2Member 2026-01-01 2026-03-31 0001460702 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001460702 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001460702 us-gaap:FairValueInputsLevel1Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel2Member 2025-01-01 2025-12-31 0001460702 us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-12-31 0001460702 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001460702 us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001460702 us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001460702 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001460702 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001460702 us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001460702 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-04-28 2025-04-28 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-06-04 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2026-01-28 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2026-01-01 2026-03-31 0001460702 AIXC:TwoThounsandTwentyFiveConvertibleNoteMember 2025-01-01 2025-12-31 0001460702 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001460702 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001460702 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001460702 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001460702 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001460702 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001460702 AIXC:UpfrontPaymentMember AIXC:LicenseAgreementMember 2022-01-01 2022-01-31 0001460702 AIXC:LicenseAgreementMember 2022-01-01 2022-01-31 0001460702 AIXC:LicenseAgreementMember 2026-01-01 2026-03-31 0001460702 AIXC:LicenseAgreementMember 2025-01-01 2025-03-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2019-03-01 2019-03-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2023-01-01 2023-12-31 0001460702 AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MinimumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MaximumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseOneClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseTwoClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:PhaseThreeClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 AIXC:LicensedProductSalesMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-01 2020-07-31 0001460702 srt:MinimumMember AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-31 0001460702 srt:MaximumMember AIXC:SponsoredResearchAgreementAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2020-07-31 0001460702 AIXC:SponsoredResearchAgreementsAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2026-01-01 2026-03-31 0001460702 AIXC:SponsoredResearchAgreementsAndLicenseMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2025-01-01 2025-03-31 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2018-06-01 2022-04-30 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 srt:MinimumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 srt:MaximumMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseOneClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseTwoClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:PhaseThreeClinicalTrialMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:LicensedProductSalesMember AIXC:LicenseAndSponsoredResearchAgreementsMember AIXC:UniversityOfLouisvilleResearchFoundationMember 2018-06-01 2022-04-30 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2026-01-01 2026-03-31 0001460702 AIXC:LicenseAndSponsoredResearchAgreementsMember 2025-01-01 2025-03-31 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-11 2024-04-11 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-11 0001460702 AIXC:CoDevelopmentAgreementMember 2024-04-12 0001460702 us-gaap:InvestorMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:LegalFirmMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:AdvisorMember AIXC:FaradaySubscriptionAgreementMember 2025-09-29 2025-09-29 0001460702 AIXC:FaradaySubscriptionAgreementMember 2026-03-31 0001460702 srt:MaximumMember us-gaap:CommonStockMember AIXC:CommonStockPurchaseAgreementMember 2024-11-19 2024-11-19 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2026-03-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2026-03-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-09-29 2025-09-29 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2025-09-29 0001460702 2024-09-06 2024-09-06 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-07-28 2025-07-28 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-07-28 0001460702 2025-07-28 2025-07-28 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 2024-11-20 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:YiHuaChenMember AIXC:SeriesA2ConvertiblePreferredStockMember 2024-11-18 2024-11-18 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001460702 srt:MaximumMember AIXC:SeriesA2AndA3ConvertiblePreferredStockMember 2025-12-31 0001460702 srt:MinimumMember AIXC:SeriesA2AndA3ConvertiblePreferredStockMember 2025-12-31 0001460702 AIXC:SeriesA3ConvertiblePreferredStockMember 2024-11-20 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2024-11-20 0001460702 us-gaap:EmployeeStockOptionMember AIXC:TwoThousandTwentyFiveStockIncentivePlanMember 2026-03-31 0001460702 us-gaap:WarrantMember 2026-03-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2024-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-03-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-03-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-03-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-03-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2025-03-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2025-03-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2026-03-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2022-12-22 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2023-12-05 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2026-03-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-26 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember 2024-02-27 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-06 0001460702 AIXC:AlphaCapitalMember 2024-09-06 2024-09-06 0001460702 AIXC:YiHuaChenMember AIXC:SecuritiesPurchaseAgreementMember 2024-04-12 0001460702 AIXC:AlphaCapitalMember 2024-09-09 0001460702 AIXC:AlphaCapitalMember 2024-09-09 2024-09-09 0001460702 AIXC:PreFundedWarrantsMember 2024-09-06 0001460702 AIXC:PreFundedWarrantsMember 2024-01-01 2024-12-31 0001460702 AIXC:PreFundedWarrantsMember 2026-03-31 0001460702 us-gaap:WarrantMember 2024-09-06 2024-09-06 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-11-20 0001460702 AIXC:CompensatoryWarrantActivityMember 2024-11-20 2024-11-20 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 0001460702 us-gaap:ConvertibleDebtMember 2025-04-27 0001460702 us-gaap:ConvertibleDebtMember 2025-04-28 2025-04-28 0001460702 AIXC:PlacementAgentWarrantsMember 2025-09-29 0001460702 AIXC:PlacementAgentWarrantsMember 2026-03-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2026-01-01 2026-03-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2026-01-01 2026-03-31 0001460702 AIXC:SeriesA2ConvertiblePreferredStockMember 2026-03-31 0001460702 AIXC:SeriesBConvertiblePreferredStockMember 2026-03-31 0001460702 us-gaap:WarrantMember 2026-03-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:CompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 srt:MinimumMember AIXC:CompensatoryWarrantActivityMember 2026-03-31 0001460702 srt:MaximumMember AIXC:CompensatoryWarrantActivityMember 2026-03-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2025-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-01-01 2025-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2026-01-01 2026-03-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2026-03-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2026-03-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2026-03-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2024-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2024-01-01 2024-12-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-01-01 2025-03-31 0001460702 AIXC:NonCompensatoryWarrantActivityMember 2025-03-31 0001460702 srt:MinimumMember AIXC:NonCompensatoryWarrantActivityMember 2025-03-31 0001460702 srt:MaximumMember AIXC:NonCompensatoryWarrantActivityMember 2025-03-31 0001460702 us-gaap:PrivatePlacementMember 2026-03-31 0001460702 us-gaap:ExecutiveCommitteeMember AIXC:LeadInvestorAgreementMember 2026-01-01 2026-03-31 0001460702 srt:ChiefExecutiveOfficerMember AIXC:LeadInvestorAgreementMember 2026-01-01 2026-03-31 0001460702 srt:PresidentMember AIXC:LeadInvestorAgreementMember 2026-01-01 2026-03-31 0001460702 AIXC:MasterServiceAgreementMember 2026-01-01 2026-03-31 0001460702 us-gaap:RelatedPartyMember AIXC:MasterServiceAgreementMember 2025-12-31 0001460702 AIXC:FaradayFutureGlobalPartnersMember 2025-01-01 2025-12-31 0001460702 AIXC:FaradayFutureGlobalPartnersMember 2026-01-01 2026-03-31 0001460702 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001460702 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-12-31 0001460702 AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-02-27 0001460702 AIXC:AlphaCapitalMember AIXC:NoncompensatoryEquityClassifiedWarrantsMember 2024-09-05 0001460702 2024-04-12 2024-04-12 0001460702 2024-04-12 0001460702 AIXC:SegmentReportingExpenseInformationMember 2026-01-01 2026-03-31 0001460702 AIXC:SegmentReportingExpenseInformationMember 2025-01-01 2025-03-31 0001460702 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-04-14 2026-04-14 0001460702 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-04-14 0001460702 us-gaap:SubsequentEventMember 2026-04-10 0001460702 us-gaap:SubsequentEventMember 2026-04-17 iso4217:USD shares iso4217:USD shares pure AIXC:Integer AIXC:Segment false Q1 --12-31 0001460702

10-Q true 2026-03-31 2026 false AIxCrypto Holdings, Inc. DE 001-37428 26-3474527 1990 E. Grand Ave. El Segundo CA 90245 (760) 452-8111 Common Stock, par value $.001 per share AIXC NASDAQ Yes Yes Non-accelerated Filer true false false 20234993 0.001

6201121

19332707

6197267

10250497

10000000

701368

1028506

4700000

4600000

385428

343060

23485184

30954770

406149

314727

10349

416498

325076

23901682

31279846

1476668

1259944

447958

1648945

33245

136234

72218 141878

142236

2030089

3329237

0.001

7000

601

659040

0.001

500000

6085

39943

4750538

31183357

4750538

31183357

0.001

225000000

20234993

5160383

84813

69738

162483668

136065924

-146106466

-140027450

21871593

27950609

23901682

31279846

3547853

2494532

638222

5072

33167

142574 197000

4333721

2724699

-4333721

-2724699

69660 39224 10236

182619

73615

303010

112953

-1945582

-1745295

78562

-6079016

-2646137

-6079016

-2646172

-0.79

-1.82

7704597

1456714

601

659040

39943

31183357

5160383

69738

136065924

-140027450

27950609

-33858 -26432819 15074610 15075 26417744

-6079016

601

659040

6085

4750538

20234993

84813

162483668

-146106466

21871593

6256

5716400

736431

65314

119958897

-123061575

2679036

6256

5716400

736431

65314

119958897

-123061575

2679036

-3236 -2893306 888879 889 2892417

269

-2646172

3020

2823094

1625310

66203

122851583

-125707745

33134

3020

2823094

1625310

66203

122851583

-125707745

33134

-6079016

-2646172

269

-69660

-39225

10236

142574

197000

182619

184942 110871

73615

-1945582

337839

-327138

-913454

216724

-37330

-102989

59861

-1200987

-4495354

-1589396

305000

10000000

338102

2107911

274041

-8504232

-305000

132000

750000

-132000

750000

-13131586

-1144396

19332707

1174608

6201121

30210

26432819

2893306

<p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zRChgz9W2O19" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in">NOTE 1 — BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES Corporate History Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio. In 2022, the Company acquired a <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z59uDbP8roaa" title="Voting interests acquired">52.8% interest in NanoSynex, Ltd. (“NanoSynex”). In 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which resulted in the Company losing its controlling interest in NanoSynex. In September 2025 the Company consummated a Subscription Agreement (the “Subscription Agreement”) with certain investors including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (the “Lead Investor” or “Faraday”) pursuant to which the investors purchased $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z2xCD5huBbGg" title="Proceeds from issuance of common stock">40.7 million (the “Offering”) of the Company’s common stock and shares of a newly created Series B Convertible Preferred Stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmI93KU555cc" title="Preferred stock, par value">0.001 per share (the “Series B Preferred Stock”) (see Note 14 - Stockholders’ Equity). This offering resulted in $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zpYDImRTMJke" title="Net proceeds">37.7 million in net proceeds after $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zB2Sge5ArHq8" title="Issuance costs">3.0 million in issuance costs were deducted. Up to $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z7lTXtbpEbwf" title="Net proceeds from the Offerings">6.8 million of the net proceeds from the Offering were used to pay existing debt and fund the Company’s existing business operations, and the balance of the cash proceeds and contributed currency will be used for the execution of the Company’s cryptocurrency treasury strategy. In January 2026, the Company formed three new wholly owned Delaware subsidiaries: AIxCrypto Token Labs US, Inc., AIxCrypto EAI, Inc., and AIxCrypto C10 ETF, Inc. These entities were formed to provide potential future organizational flexibility. As of March 31, 2026, these subsidiaries have not commenced operations, hold no material assets, and have not been capitalized. Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2025 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The interim results for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any future periods. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In general, the functional currency of the Company is the U.S. dollar. There were no foreign currency transactions in the three months ending March 31, 2026 and 2025. Accounting Estimates Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The Company’s estimates relate to the estimated fair value of convertible debt, warrant liabilities, and determination of the allowance for credit losses. Actual results could vary from the estimates that were used. <p id="xdx_843_ecustom--RelatedPartiesAndRelatedPartyTransactionsPolicyTextBlock_zrsKZ7FUVUef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Related Parties and Related Party Transactions A related party is a person who has the ability to exert significant influence over the Company and may include executive officers and directors, including members of their immediate families, shareholders owning more than 10% of the Company’s voting securities, or other entities deemed to be affiliates, as defined in ASC 850, Related Party Disclosures. The Company assesses its related parties and applicable disclosures on a quarterly basis, considering all relevant facts and circumstances. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. As of December 31, 2025, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts. <p id="xdx_843_ecustom--PlatformOperatorsCryptoAssetPolicyTextBlock_zbZMHGDNykh8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Digital Assets The Company accounts for its digital assets in accordance with ASC 350, Intangibles—Goodwill and Other, as amended by ASU 2023-08, Accounting for and Disclosure of Crypto Assets. The Company adopted ASU 2023-08 effective January 1, 2025. Digital assets held by the Company, including Bitcoin, Cardano, Chainlink, Ethereum, Native BNB, Ripple, Solana, Tether (“USDT”), and Tron, meet the scope criteria of ASU 2023-08 and are recognized as indefinite-lived intangible assets. These assets are initially recorded at cost , including transaction fees, upon obtaining control of the asset, and are measured subsequently at fair value with changes in value recognized in net income or loss. The Company uses a FIFO methodology to assign costs to digital assets for purposes of the digital assets held and realized gains and losses disclosures. Purchases and sales of digital assets that are not revenue arrangements are classified on the statement of cash flows as investing activities. Net loss on digital assets are adjusted in operating activities in the statement of cash flows. Prepaid Investments The Company records cash advances made in connection with contractually committed equity investments for which the underlying securities have not yet been issued or settled as prepaid investments. Prepaid investments are initially recognized at cost and classified as current or noncurrent assets based on the expected timing of settlement. Upon issuance and receipt of the underlying equity securities, the prepaid investment is derecognized and reclassified to the appropriate account in accordance with applicable U.S. GAAP. Management monitors the status of the underlying transaction and evaluates the prepaid investment for recoverability. Software Capitalization The Company accounts for the costs incurred in developing its product offerings under ASC 350-40, Internal-Use Software. In accordance with the guidance in ASC 350-40, the Company will capitalize costs incurred in connection with the development of the Company’s product offerings during the application development stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred in connection with maintenance activities, including training or bug fixes are also expensed as incurred. The Company stops capitalizing qualifying costs once development activities are completed and the project is ready for its intended use. Capitalized software costs will be amortized on a straight-line basis over a 36-month useful life beginning on the date when the product is ready for its intended use. Management will subsequently test the capitalized software costs for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable in accordance with ASC 360. <p id="xdx_84B_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zLBNnqvji24f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 8 – Warrant Liabilities). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are unobservable.</td></tr> </table> Fair Value of Financial Instruments Cash, prepaid expenses, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Short-term notes receivable are valued subject to a current expected credit loss (“CECL”) model (see Note 6 - Short-Term Notes Receivable). The value of the Company’s warrant liabilities as of March 31, 2026 and December 31, 2025 was determined using the Black-Scholes Model. Significant assumptions used in the valuation include the expected volatility of the Company’s common stock, the contractual term of the warrants, the risk-free interest rate, and an expected dividend yield of zero. Expected volatility is based on a blend of comparable public company data and, as available, the Company’s own historical volatility. The risk-free rate is derived from U.S. Treasury yields with maturities commensurate with the remaining contractual term of the warrants. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy. The Company from time to time elects the fair value option to account for certain debt liabilities. Electing the fair value option allows the Company to initially and subsequently measure such liabilities at fair value rather than amortized cost and may be applied to debt liabilities that contain conversion or other features that would otherwise require bifurcation and mark to market accounting. Such debt liabilities will initially be measured using valuation techniques appropriate to the terms and expected life of the note. The Company expects to use level 3 input to measure the fair value in subsequent periods. <p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zuDREAOkdGt7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Sales and Marketing Sales and marketing expenses are expensed as incurred and primarily consist of direct costs associated with branding, promotional, co-creation, and publicity activities. The Company’s marketing initiatives focus on increasing brand awareness for its real-world asset tokenization and embodied AI Infrastructure activities. For the three months ending March 31, 2026 and 2025, the Company’s sales and marketing expenses were $638,222 and $0, respectively, none of which was advertising related. Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant. Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgHYA6NvUsF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Adopted Accounting Standards There have been no recently adopted accounting pronouncements by the Company. <p id="xdx_842_ecustom--AccountingStandardsUpdatesNotYetAdoptedPolicyPolicyTextBlock_zdv9OmZhfntf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Issued Accounting Standards Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies interim disclosure requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for the Company’s interim financial statements beginning with the first fiscal quarter of the year ended December 31, 2028, with early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is evaluating the disclosure requirements related to the new standard. The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our unaudited condensed consolidated financial statements or disclosures.

Corporate History Ritter Pharmaceuticals, Inc. (the Company’s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May 22, 2020, upon completing a “reverse recapitalization” transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was renamed Qualigen Therapeutics, Inc. (the “Company”). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc. was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock of Qualigen, Inc. to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned subsidiary of Biosynex, S.A. (“Biosynex”). Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio. In 2022, the Company acquired a <span id="xdx_90F_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_z59uDbP8roaa" title="Voting interests acquired">52.8% interest in NanoSynex, Ltd. (“NanoSynex”). In 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the “NanoSynex Amendment”), which resulted in the Company losing its controlling interest in NanoSynex. In September 2025 the Company consummated a Subscription Agreement (the “Subscription Agreement”) with certain investors including Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (the “Lead Investor” or “Faraday”) pursuant to which the investors purchased $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z2xCD5huBbGg" title="Proceeds from issuance of common stock">40.7 million (the “Offering”) of the Company’s common stock and shares of a newly created Series B Convertible Preferred Stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zmI93KU555cc" title="Preferred stock, par value">0.001 per share (the “Series B Preferred Stock”) (see Note 14 - Stockholders’ Equity). This offering resulted in $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zpYDImRTMJke" title="Net proceeds">37.7 million in net proceeds after $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zB2Sge5ArHq8" title="Issuance costs">3.0 million in issuance costs were deducted. Up to $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_z7lTXtbpEbwf" title="Net proceeds from the Offerings">6.8 million of the net proceeds from the Offering were used to pay existing debt and fund the Company’s existing business operations, and the balance of the cash proceeds and contributed currency will be used for the execution of the Company’s cryptocurrency treasury strategy. In January 2026, the Company formed three new wholly owned Delaware subsidiaries: AIxCrypto Token Labs US, Inc., AIxCrypto EAI, Inc., and AIxCrypto C10 ETF, Inc. These entities were formed to provide potential future organizational flexibility. As of March 31, 2026, these subsidiaries have not commenced operations, hold no material assets, and have not been capitalized.

0.528

40700000

0.001

37700000

3000000.0

6800000

Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2025 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The interim results for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any future periods.

Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In general, the functional currency of the Company is the U.S. dollar. There were no foreign currency transactions in the three months ending March 31, 2026 and 2025.

Accounting Estimates Management uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The Company’s estimates relate to the estimated fair value of convertible debt, warrant liabilities, and determination of the allowance for credit losses. Actual results could vary from the estimates that were used.

<p id="xdx_843_ecustom--RelatedPartiesAndRelatedPartyTransactionsPolicyTextBlock_zrsKZ7FUVUef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Related Parties and Related Party Transactions A related party is a person who has the ability to exert significant influence over the Company and may include executive officers and directors, including members of their immediate families, shareholders owning more than 10% of the Company’s voting securities, or other entities deemed to be affiliates, as defined in ASC 850, Related Party Disclosures. The Company assesses its related parties and applicable disclosures on a quarterly basis, considering all relevant facts and circumstances.

Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains the majority of its cash in accounts at banking institutions in the U.S. that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations. As of December 31, 2025, the Company had not experienced losses on these accounts, and management believes the Company is not exposed to significant risk on such accounts.

<p id="xdx_843_ecustom--PlatformOperatorsCryptoAssetPolicyTextBlock_zbZMHGDNykh8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Digital Assets The Company accounts for its digital assets in accordance with ASC 350, Intangibles—Goodwill and Other, as amended by ASU 2023-08, Accounting for and Disclosure of Crypto Assets. The Company adopted ASU 2023-08 effective January 1, 2025. Digital assets held by the Company, including Bitcoin, Cardano, Chainlink, Ethereum, Native BNB, Ripple, Solana, Tether (“USDT”), and Tron, meet the scope criteria of ASU 2023-08 and are recognized as indefinite-lived intangible assets. These assets are initially recorded at cost , including transaction fees, upon obtaining control of the asset, and are measured subsequently at fair value with changes in value recognized in net income or loss. The Company uses a FIFO methodology to assign costs to digital assets for purposes of the digital assets held and realized gains and losses disclosures. Purchases and sales of digital assets that are not revenue arrangements are classified on the statement of cash flows as investing activities. Net loss on digital assets are adjusted in operating activities in the statement of cash flows. Prepaid Investments The Company records cash advances made in connection with contractually committed equity investments for which the underlying securities have not yet been issued or settled as prepaid investments. Prepaid investments are initially recognized at cost and classified as current or noncurrent assets based on the expected timing of settlement. Upon issuance and receipt of the underlying equity securities, the prepaid investment is derecognized and reclassified to the appropriate account in accordance with applicable U.S. GAAP. Management monitors the status of the underlying transaction and evaluates the prepaid investment for recoverability. Software Capitalization The Company accounts for the costs incurred in developing its product offerings under ASC 350-40, Internal-Use Software. In accordance with the guidance in ASC 350-40, the Company will capitalize costs incurred in connection with the development of the Company’s product offerings during the application development stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred in connection with maintenance activities, including training or bug fixes are also expensed as incurred. The Company stops capitalizing qualifying costs once development activities are completed and the project is ready for its intended use. Capitalized software costs will be amortized on a straight-line basis over a 36-month useful life beginning on the date when the product is ready for its intended use. Management will subsequently test the capitalized software costs for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable in accordance with ASC 360. <p id="xdx_84B_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zLBNnqvji24f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 8 – Warrant Liabilities).

Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Inputs that are unobservable.</td></tr> </table>

Fair Value of Financial Instruments Cash, prepaid expenses, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Short-term notes receivable are valued subject to a current expected credit loss (“CECL”) model (see Note 6 - Short-Term Notes Receivable). The value of the Company’s warrant liabilities as of March 31, 2026 and December 31, 2025 was determined using the Black-Scholes Model. Significant assumptions used in the valuation include the expected volatility of the Company’s common stock, the contractual term of the warrants, the risk-free interest rate, and an expected dividend yield of zero. Expected volatility is based on a blend of comparable public company data and, as available, the Company’s own historical volatility. The risk-free rate is derived from U.S. Treasury yields with maturities commensurate with the remaining contractual term of the warrants. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy. The Company from time to time elects the fair value option to account for certain debt liabilities. Electing the fair value option allows the Company to initially and subsequently measure such liabilities at fair value rather than amortized cost and may be applied to debt liabilities that contain conversion or other features that would otherwise require bifurcation and mark to market accounting. Such debt liabilities will initially be measured using valuation techniques appropriate to the terms and expected life of the note. The Company expects to use level 3 input to measure the fair value in subsequent periods.

<p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zuDREAOkdGt7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Sales and Marketing Sales and marketing expenses are expensed as incurred and primarily consist of direct costs associated with branding, promotional, co-creation, and publicity activities. The Company’s marketing initiatives focus on increasing brand awareness for its real-world asset tokenization and embodied AI Infrastructure activities. For the three months ending March 31, 2026 and 2025, the Company’s sales and marketing expenses were $638,222 and $0, respectively, none of which was advertising related.

638222

Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.

Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years.

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zgHYA6NvUsF8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Adopted Accounting Standards There have been no recently adopted accounting pronouncements by the Company.

<p id="xdx_842_ecustom--AccountingStandardsUpdatesNotYetAdoptedPolicyPolicyTextBlock_zdv9OmZhfntf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently Issued Accounting Standards Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies interim disclosure requirements resulting in a comprehensive list of interim disclosures that are required by GAAP, and includes a disclosure principle that requires the disclosure of events since the end of the last annual reporting period that have a material impact on the Company. ASU 2025-11 is effective for the Company’s interim financial statements beginning with the first fiscal quarter of the year ended December 31, 2028, with early adoption permitted. ASU 2025-11 may be applied either prospectively or retrospectively. The Company is evaluating the disclosure requirements related to the new standard. The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our unaudited condensed consolidated financial statements or disclosures.

<p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z51Wo9qJnop9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 2 — LIQUIDITY AND GOING CONCERN As of March 31, 2026, the Company had approximately $6.2 million in cash and cash equivalents and an accumulated deficit of approximately $146.1 million. For the three months ended March 31, 2026, the Company used approximately $4.5 million of cash in operating activities, and for the year ended December 31, 2025, approximately $7.0 million. The Company generated no revenue during either period and has incurred recurring net losses. While the Company raised significant capital during the year ended December 31, 2025, including net proceeds of $37.7 million from the Subscription Agreement in September 2025, a portion of those proceeds was used to repay existing debt and fund the company’s existing research and development operations, and the remaining balance was largely deployed to support the Company’s cryptocurrency treasury initiatives. Further, the Company has not raised capital during the three months ended March 31, 2026, and has no committed sources of additional financing as of the date of issuance of these financial statements. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ from those reflected in the accompanying financial statements.

6200000

-146100000

-4500000

-7000000.0

37700000

NOTE 3 — DIGITAL ASSETS As part of its strategic realignment completed in the fourth quarter of 2025, the Company began acquiring digital assets for investment purposes and for use within its programmable technology infrastructure platform. The Company holds digital assets consisting of cryptocurrencies, stablecoins, and other blockchain-based tokens, as detailed below. Significant Holdings As of March 31, 2026, the Company’s significant digital asset holdings consisted of the following: SCHEDULE OF CRYPTO ASSET HOLDINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Units Held</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Cardano ADA (ADA)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_zHoMl8aKhU73" style="width: 14%; text-align: right" title="Crypto asset number of units">214,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_zUKgFomVr8ec" style="width: 14%; text-align: right" title="Crypto asset cost basis">134,404</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_z9CWaa4x6Qn7" style="width: 14%; text-align: right" title="Crypto asset fair value">51,866</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Native BNB (BSC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zDEgsdL4KGvf" style="text-align: right" title="Crypto asset number of units">1,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zpcJzT21SSZ7" style="text-align: right" title="Crypto asset cost basis">1,356,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zn6fS4O3SbOc" style="text-align: right" title="Crypto asset fair value">806,949</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bitcoin (BTC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zavLUnbunKQ6" style="text-align: right" title="Crypto asset number of units">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zwva9nOgazEf" style="text-align: right" title="Crypto asset cost basis">4,943,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zC7hsZ5cF4l1" style="text-align: right" title="Crypto asset fair value">3,150,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Ethereum (ETH)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_zXSnCXNzU4ee" style="text-align: right" title="Crypto asset number of units">616</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_ztUBMUaQeYc8" style="text-align: right" title="Crypto asset cost basis">2,307,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_zHCcgcG0gsz8" style="text-align: right" title="Crypto asset fair value">1,296,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">ChainLink (LINK)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zeG0TxQFUHhf" style="text-align: right" title="Crypto asset number of units">19,404</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zHfF8vL92JO5" style="text-align: right" title="Crypto asset cost basis">338,489</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zWGDfXsH4Wt4" style="text-align: right" title="Crypto asset fair value">170,251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Solana (SOL)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_znreNTBCZvXc" style="text-align: right" title="Crypto asset number of units">6,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_z14ui3Ccd797" style="text-align: right" title="Crypto asset cost basis">1,188,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_zYTIgjgYszEh" style="text-align: right" title="Crypto asset fair value">553,152</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tron (TRX)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--TronMember_ztq15bqLWHff" style="text-align: right" title="Crypto asset number of units">531,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--TronMember_zmxSGobzaui" style="text-align: right" title="Crypto asset cost basis">163,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--TronMember_z4I6Acps7Fm2" style="text-align: right" title="Crypto asset fair value">166,414</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">USD Tether (USDT)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_zuGT7T9vMjh7" style="text-align: right" title="Crypto asset number of units">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_z0sMb0IJHPN4" style="text-align: right" title="Crypto asset cost basis">2,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_zW7EIllSfMl5" style="text-align: right" title="Crypto asset fair value">2,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ripple (XRP)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--RippleMember_z62QQaTQ9sG4" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset number of units">1</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--RippleMember_zgU6TzEfstsb" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset cost basis">3</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--RippleMember_ziz6Tin0qq83" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset fair value">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--CryptoAssetCost_iI_c20260331_ziDulEQvMwN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset cost basis">10,433,028</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CryptoAssetFairValue_iI_c20260331_zptNW2LBlSC4" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset fair value">6,197,267</td><td style="text-align: left"> </td></tr> </table> Digital Asset Activity The following table summarizes digital asset activity for the period indicated, including cost basis, fair value at the time of sale, realized and unrealized losses, and the fair value of outstanding digital assets as of March 31, 2026: SCHEDULE OF DIGITAL ASSET ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260101__20260331_zqYZMwO6NtSj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetFairValue_iS_zbcGte6YwDHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,250,497</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetPurchase_zW5plgu7F5U5" style="vertical-align: bottom; background-color: transparent"> <td>Additions(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">338,102</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetSale_iN_di_zwnVWPCSnRq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dispositions(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,107,911</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetUnrealizedGainOperating_z49tb6NCGYXa" style="vertical-align: bottom; background-color: transparent"> <td>Gains(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_di_zs5YRQPJzXGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Losses(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,309,609</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetPaymentForService_iN_di_zZ6mBXMieu73" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">Payments made</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(337,839</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetFairValue_iE_ze2mOlKtPn0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,197,267</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in">(1)</td> <td style="text-align: justify">Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto assets held for investment</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="text-align: justify">(2)</td> <td style="text-align: justify">The Company measures gains and losses by each asset held. These amounts include cumulative unrealized gains of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--CryptoAssetUnrealizedGainOperating_c20260101__20260331_zuUQ7EMxZ284" title="Unrealized gains of digital assets">364,027, realized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--CryptoAssetRealizedLossOperating_c20260101__20260331_zNnJ33EQ5PW9" title="Realized loss of digital assets">398,720, and unrealized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--CryptoAssetUnrealizedLossOperating_c20260101__20260331_z2DLEPliTYTl" title="Unrealized loss of digital assets">1,910,889 during the three months ended March 31, 2026</td></tr> </table> There were no digital assets held during the three months ended March 31, 2025. The Company measures digital assets at fair value in accordance with ASC 820, Fair Value Measurement. Fair value is determined using quoted prices in active markets for identical assets (Level 1 inputs). The Company utilizes pricing information provided by the principal market, which is based on observable market prices from active trading exchanges.

As of March 31, 2026, the Company’s significant digital asset holdings consisted of the following: SCHEDULE OF CRYPTO ASSET HOLDINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Units Held</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Cardano ADA (ADA)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_zHoMl8aKhU73" style="width: 14%; text-align: right" title="Crypto asset number of units">214,323</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_zUKgFomVr8ec" style="width: 14%; text-align: right" title="Crypto asset cost basis">134,404</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--CardanoADAMember_z9CWaa4x6Qn7" style="width: 14%; text-align: right" title="Crypto asset fair value">51,866</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Native BNB (BSC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zDEgsdL4KGvf" style="text-align: right" title="Crypto asset number of units">1,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zpcJzT21SSZ7" style="text-align: right" title="Crypto asset cost basis">1,356,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--NativeBNBMember_zn6fS4O3SbOc" style="text-align: right" title="Crypto asset fair value">806,949</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bitcoin (BTC)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zavLUnbunKQ6" style="text-align: right" title="Crypto asset number of units">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zwva9nOgazEf" style="text-align: right" title="Crypto asset cost basis">4,943,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--BitcoinMember_zC7hsZ5cF4l1" style="text-align: right" title="Crypto asset fair value">3,150,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Ethereum (ETH)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_zXSnCXNzU4ee" style="text-align: right" title="Crypto asset number of units">616</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_ztUBMUaQeYc8" style="text-align: right" title="Crypto asset cost basis">2,307,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--EthereumMember_zHCcgcG0gsz8" style="text-align: right" title="Crypto asset fair value">1,296,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">ChainLink (LINK)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zeG0TxQFUHhf" style="text-align: right" title="Crypto asset number of units">19,404</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zHfF8vL92JO5" style="text-align: right" title="Crypto asset cost basis">338,489</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--ChainLinkMember_zWGDfXsH4Wt4" style="text-align: right" title="Crypto asset fair value">170,251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Solana (SOL)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_znreNTBCZvXc" style="text-align: right" title="Crypto asset number of units">6,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_z14ui3Ccd797" style="text-align: right" title="Crypto asset cost basis">1,188,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--SolanaMember_zYTIgjgYszEh" style="text-align: right" title="Crypto asset fair value">553,152</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Tron (TRX)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--TronMember_ztq15bqLWHff" style="text-align: right" title="Crypto asset number of units">531,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--TronMember_zmxSGobzaui" style="text-align: right" title="Crypto asset cost basis">163,542</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--TronMember_z4I6Acps7Fm2" style="text-align: right" title="Crypto asset fair value">166,414</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">USD Tether (USDT)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_zuGT7T9vMjh7" style="text-align: right" title="Crypto asset number of units">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_z0sMb0IJHPN4" style="text-align: right" title="Crypto asset cost basis">2,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--USDTetherMember_zW7EIllSfMl5" style="text-align: right" title="Crypto asset fair value">2,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Ripple (XRP)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260331__srt--CryptoAssetAxis__custom--RippleMember_z62QQaTQ9sG4" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset number of units">1</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CryptoAssetCost_iI_c20260331__srt--CryptoAssetAxis__custom--RippleMember_zgU6TzEfstsb" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset cost basis">3</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CryptoAssetFairValue_iI_c20260331__srt--CryptoAssetAxis__custom--RippleMember_ziz6Tin0qq83" style="border-bottom: Black 1pt solid; text-align: right" title="Crypto asset fair value">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--CryptoAssetCost_iI_c20260331_ziDulEQvMwN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset cost basis">10,433,028</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--CryptoAssetFairValue_iI_c20260331_zptNW2LBlSC4" style="border-bottom: Black 2.5pt double; text-align: right" title="Crypto asset fair value">6,197,267</td><td style="text-align: left"> </td></tr> </table>

214323

134404

51866

1308

1356162

806949

4943027

3150211

616

2307312

1296074

19404

338489

170251

6659

1188004

553152

531334

163542

166414

2087

2085

2349

10433028

6197267

The following table summarizes digital asset activity for the period indicated, including cost basis, fair value at the time of sale, realized and unrealized losses, and the fair value of outstanding digital assets as of March 31, 2026: SCHEDULE OF DIGITAL ASSET ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260101__20260331_zqYZMwO6NtSj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetFairValue_iS_zbcGte6YwDHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,250,497</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetPurchase_zW5plgu7F5U5" style="vertical-align: bottom; background-color: transparent"> <td>Additions(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">338,102</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetSale_iN_di_zwnVWPCSnRq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dispositions(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,107,911</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--CryptoAssetUnrealizedGainOperating_z49tb6NCGYXa" style="vertical-align: bottom; background-color: transparent"> <td>Gains(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_di_zs5YRQPJzXGk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Losses(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,309,609</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetPaymentForService_iN_di_zZ6mBXMieu73" style="vertical-align: bottom; background-color: transparent"> <td style="text-align: left">Payments made</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(337,839</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetFairValue_iE_ze2mOlKtPn0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,197,267</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.5in">(1)</td> <td style="text-align: justify">Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto assets held for investment</td></tr> <tr style="vertical-align: top; text-align: left"> <td style="text-align: justify">(2)</td> <td style="text-align: justify">The Company measures gains and losses by each asset held. These amounts include cumulative unrealized gains of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--CryptoAssetUnrealizedGainOperating_c20260101__20260331_zuUQ7EMxZ284" title="Unrealized gains of digital assets">364,027, realized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--CryptoAssetRealizedLossOperating_c20260101__20260331_zNnJ33EQ5PW9" title="Realized loss of digital assets">398,720, and unrealized losses of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIERJR0lUQUwgQVNTRVQgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--CryptoAssetUnrealizedLossOperating_c20260101__20260331_z2DLEPliTYTl" title="Unrealized loss of digital assets">1,910,889 during the three months ended March 31, 2026</td></tr> </table>

10250497

338102

2107911

364027

2309609

337839

6197267

364027

398720

1910889

NOTE 4 — FAIR VALUE MEASUREMENTS <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zIGw55tudobd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of March 31, 2026: SCHEDULE OF FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeq2FBaTicy3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQde3xfdapV9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNLfJyJu8Npj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_zowEDXTt4Ba4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zpsOM4ruIABb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zLA3v0Fz3Cf5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,932,305</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,932,305</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_znm1hD1obQuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Digital Assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,197,267</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,197,267</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_zhjSjelSYE58" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,129,572</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,129,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_z3UCXezgJ9J3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zHaqsFLV65Wj" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_z8lSMA8UIGd3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant Liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,218</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_zJGmsjRm2goi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td></tr> </table> Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcgf5ZqUp0fj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1nXY0ydBck9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEJkgTlGaAr" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20251231_zPNS4QkPP7X6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_z6bcsOShwtWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zFXk9Oj2ywSh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_zZMHPY8vne2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Digital Assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_z8YslqojSCZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zL6b7ZetjtB4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_z0SzNNC7lKPc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_z5m15ZGdpPCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant Liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_zvPEvVsh3In1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zIGw55tudobd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of March 31, 2026: SCHEDULE OF FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeq2FBaTicy3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQde3xfdapV9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNLfJyJu8Npj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_zowEDXTt4Ba4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zpsOM4ruIABb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zLA3v0Fz3Cf5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,932,305</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,932,305</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_znm1hD1obQuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Digital Assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,197,267</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,197,267</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_zhjSjelSYE58" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,129,572</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,129,572</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_z3UCXezgJ9J3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zHaqsFLV65Wj" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_z8lSMA8UIGd3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant Liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,218</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_zJGmsjRm2goi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td></tr> </table> Below is the summary of our assets and liabilities measured at fair value on a recurring basis and categorized using the fair value hierarchy as of December 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcgf5ZqUp0fj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1nXY0ydBck9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEJkgTlGaAr" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20251231_zPNS4QkPP7X6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosureAbstract_iB_z6bcsOShwtWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--MoneyMarketFundsFairValueDisclosure_iI_zFXk9Oj2ywSh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Money Market funds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">15,957,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iI_zZMHPY8vne2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Digital Assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,250,497</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_iI_z8YslqojSCZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,207,676</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zL6b7ZetjtB4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_z0SzNNC7lKPc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Convertible Debt</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--WarrantLiabilitiesFairValueDisclosures_iI_z5m15ZGdpPCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant Liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">141,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iI_zvPEvVsh3In1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,114</td><td style="text-align: left"> </td></tr> </table>

5932305 5932305

6197267

12129572

72218 72218

72218

15957179 15957179

10250497

26207676

142236

141878 141878

284114

NOTE 5 — PREPAID INVESTMENT, PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid Investment – related party As of March 31, 2026, the Company recorded a prepaid investment of $10.0 million, representing cash advanced in connection with a contractually committed equity investment for which the underlying securities have not yet been issued or settled. On January 30, 2026, the Company entered into an entrusted investment arrangement with Gold King Arthur Holding Limited (“GKA”), pursuant to which the Company engaged GKA to act as fiduciary to acquire, hold, manage, tokenize, monetize and dispose of securities of the Faraday for the benefit of the Company. In connection with the arrangement, GKA entered into a Securities Purchase Agreement (the “SPA”) with the Faraday to purchase $10.0 million of the Faraday’s Class A common stock. The arrangement provided that the Company would fund the investment principal and GKA would manage the investment and related activities. In February 2026, on behalf of GKA, the Company paid $<span id="xdx_907_eus-gaap--PaymentsToAcquireOtherInvestments_pn5n6_c20260201__20260228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FaradayFutureIntelligentElectricIncMember_z21ZqC2aN3pl" title="Prepayment of investments">10.0 million to Faraday, which is a related party, in connection with an investment arrangement pursuant to which GKA is designated to acquire shares of Faraday on behalf of the Company. As of March 31, 2026, the Faraday shares have not yet been issued to or received by GKA, and therefore the Company has not obtained ownership rights to the underlying equity securities. The prepaid investment is classified within current assets based on management’s expectation that the investment will be completed within one year. Additionally, the underlying equity to be purchased is not subject to contractual lock-ups or other restrictions that would necessitate non-current classification. Because the underlying equity securities have not been issued as of the reporting date, the prepaid investment does not represent an equity interest, investment security, or financial instrument. Accordingly, the prepaid investment is not subject to fair value measurement and is carried at cost. Upon issuance and receipt of the underlying equity securities, the prepaid investment will be derecognized and reclassified to the appropriate account and accounted for in accordance with applicable U.S. GAAP based on the nature of the Company’s interest. The underlying equity securities were issued in April 2026, which is further discussed in Note 17 – Subsequent Events. <p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zSDIr9saVNK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Prepaid expenses and other current assets consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20260331_zjemWtP9ZKh9" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231_zDVIBEc83Pp3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidConsulting_iI_pp0p0_maPEAOAzdSM_zUuxgPo0VOrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">206,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">461,337</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zN4T21wihGZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">412,127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLegal_iI_pp0p0_maPEAOAzdSM_zrxL8y5Tviwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepaid legal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,193</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzdSM_zfvpgPaQ0Ghk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other current assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,472</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,638</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_z08yRnCPhcLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Prepaid expenses and other current assets </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,368</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,028,506</td><td style="text-align: left"> </td></tr> </table>

10000000.0

<p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zSDIr9saVNK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Prepaid expenses and other current assets consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20260331_zjemWtP9ZKh9" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_497_20251231_zDVIBEc83Pp3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_ecustom--PrepaidConsulting_iI_pp0p0_maPEAOAzdSM_zUuxgPo0VOrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid consulting</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">206,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">461,337</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zN4T21wihGZc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">412,127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">481,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLegal_iI_pp0p0_maPEAOAzdSM_zrxL8y5Tviwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepaid legal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,193</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAssetsCurrent_iI_pp0p0_maPEAOAzdSM_zfvpgPaQ0Ghk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other current assets</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,472</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,638</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_z08yRnCPhcLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Prepaid expenses and other current assets </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">701,368</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,028,506</td><td style="text-align: left"> </td></tr> </table>

206994 461337

412127

481338

31775 84193

50472

1638

701368

1028506

<p id="xdx_801_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zYlPgzab75vc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 6 —SHORT-TERM NOTES RECEIVABLE <p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zwFMyoAViSP1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Short term notes receivable - consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF SHORT-TERM NOTE RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20260331_zHFlTksIBWAk" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20251231_zY9rd32uxbPj" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_maNALRNzwcc_zkf1zWkznucf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short-term note receivable - Marizyme</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,083,002</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,898,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_msNALRNzwcc_zdEQovLsI5Eh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less allowance for credit losses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,697,574</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,555,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNzwcc_zdRGVkkScsS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Short-term notes receivable </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">385,428</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">343,060</td><td style="text-align: left"> </td></tr> </table> During the year ended December 31, 2025, the Company advanced to Marizyme, Inc. $1,909,500, against which Marizyme delivered demand promissory notes to the Company of like principal amounts (the “Marizyme Notes”). As of March 31, 2026 and December 31, 2025 accrued interest related to the Marizyme Notes was $916,102 and $731,160, respectively and for the three months ended March 31, 2026 and 2025 interest income of $<span id="xdx_905_ecustom--AccruedInterestOnShorttermNoteReceivable_c20260101__20260331__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--OtherIncomeMember_ztmaRXkhZzb8" title="Accrued interest on short-term note receivable">184,942 and $<span id="xdx_90F_ecustom--AccruedInterestOnShorttermNoteReceivable_c20250101__20250331__us-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--OtherIncomeMember_zyGBRlpUG3Wh" title="Accrued interest on short-term note receivable">110,871, respectively, was recognized in other income in the unaudited condensed consolidated statement of operations. The Marizyme Notes bear at interest the rate of eighteen percent (18%) per annum. Marizyme may pre-pay all or any part of the outstanding principal or interest at any time and from time to time, in whole or in part, without premium or penalty. Under ASC 326-20, known as the current expected credit loss (“CECL”) model, the Company was required to estimate credit losses expected over the life of an exposure (or pool of exposures) based on historical information, current information, and reasonable and supportable forecasts. The Company is unable to use its historical data to estimate losses as it has no relevant loss history to date. To determine the estimate of expected credit losses, the Company used a probability-weighted approach that incorporates multiple settlement scenarios, including recovery of amounts due upon an acquisition of the debtor, and recovery in different liquidation scenarios, and determines the expected recoverable amount of the loan in each scenario. This model requires management to make certain assumptions including the likelihood of each outcome, the estimated value of the debtor’s assets, and the Company’s expected claim and recovery rate on the debtor’s assets in the event of an insolvency or a liquidation proceeding. As of March 31, 2026, the estimate for expected credit losses on the Marizyme Notes is $4,697,574. Given the inherently uncertain nature of the debtor’s financial condition and future outcomes, actual credit losses may differ materially from this estimate. The Company will continue to monitor relevant events and conditions and update its assumptions and allowance as necessary. The Company is also party to a Co-Development Agreement with Marizyme (see Note 13 - Research and License Agreements).

<p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zwFMyoAViSP1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Short term notes receivable - consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF SHORT-TERM NOTE RECEIVABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20260331_zHFlTksIBWAk" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20251231_zY9rd32uxbPj" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_maNALRNzwcc_zkf1zWkznucf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short-term note receivable - Marizyme</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,083,002</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,898,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_msNALRNzwcc_zdEQovLsI5Eh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less allowance for credit losses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,697,574</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,555,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNzwcc_zdRGVkkScsS5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Short-term notes receivable </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">385,428</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">343,060</td><td style="text-align: left"> </td></tr> </table>

5083002

4898060

4697574

4555000

385428

343060

1909500

916102

731160

184942 110871

0.18

4697574

<p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zw4cW0W9Fi8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 7 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zvxHphuCkAjb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Accrued expenses and other current liabilities consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_zJFWNggU15Ee" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20251231_zBg4RFKPLGG3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzOMI_zHSfNMrQRaj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">License fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedCreditCard_iI_pp0p0_maALCzOMI_zYnSSu7kSMud" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzOMI_zcwqQqTwg3Eb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,434</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCzOMI_zq6jf7NMFWIf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee benefits</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,465</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzOMI_zDyFQ2LN32pl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accrued expenses and other current liabilities </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,245</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">136,234</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zvxHphuCkAjb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Accrued expenses and other current liabilities consisted of the following at March 31, 2026 and December 31, 2025: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_zJFWNggU15Ee" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20251231_zBg4RFKPLGG3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzOMI_zHSfNMrQRaj9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">License fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">20,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedCreditCard_iI_pp0p0_maALCzOMI_zYnSSu7kSMud" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzOMI_zcwqQqTwg3Eb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115,434</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCzOMI_zq6jf7NMFWIf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee benefits</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,465</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzOMI_zDyFQ2LN32pl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accrued expenses and other current liabilities </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33,245</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">136,234</td><td style="text-align: left"> </td></tr> </table>

20000 800

31780

115434

1465

33245

136234

NOTE 8 – WARRANT LIABILITIES On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock (see Note 14 – Stockholders Equity). As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified warrants’ respective terms, and concluded that warrants for <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241120__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzrwSD2SFqE1" title="Warrants to purchase common shares">68,712 common shares with a weighted average exercise price of $2.00 were required to be reclassified to liabilities, including pre-funded warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zZXT875qiua9" title="Warrants exercise price">0.05 per share. The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. At March 31, 2026, pre-funded warrants for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zhz10VogezLi" title="Warrants to purchase common shares">51,199 common shares remained outstanding. During the three months ended March 31, 2026 and 2025 the Company recorded a gain on change in fair value of warrant liabilities of $<span id="xdx_90A_ecustom--GainLossOnChangeInFairValueOfWarrantLiabilities_di_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zXS0muihxcjf" title="Fair value of warrant liabilities">69,660 and $<span id="xdx_903_ecustom--GainLossOnChangeInFairValueOfWarrantLiabilities_di_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_z3BjkGJZtSy7" title="Fair value of warrant liabilities">39,224, respectively for these warrants. At March 31, 2026 and December 31, 2025, the fair value of these warrants was $72,218 and $141,878, respectively. <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDfXm3tIKiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the activity in liability classified warrants for the three months ended March 31, 2026: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLEUWvzhsfse" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">67,218</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeHZgZK7Idxg" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zlWZfCfox879" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zhiKISKuqd92" title="Range of Exercise Price, Beginning">7.80 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zDDPwKumSIf3" title="Weighted - Average Remaining Life (Years) Outstanding">3.68</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zq4lzljHIxu4" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbMkcW1idpT4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceGranted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYcbbKt3xhKl" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMUpruAwPU" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMRyQCDP7Vq1" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceExcercised_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzkvIUXJLg12" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlaRUjDD3Fs1" style="text-align: right" title="Number of Shares, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFcaYHcmbrNh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt1wDF7HzDnf" title="Range of Exercise Price, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEMgsPCqOoe4" style="text-align: right" title="Number of Shares, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zul9LLUXM4X5" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zyyNJJidcJcf" title="Range of Exercise Price, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRC93G9DQYFh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxBdI09Kd9Vb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--RangeOfExpiredPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJvvjUYDEgX7" title="Range of Expired Price">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total outstanding –March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXD8bRG6dnOa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">67,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPtySWmTmnt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.90</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zGExJ2eKyrD" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_z3e7wwuQvU23" title="Range of Exercise Price, Ending">7.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zNNxUtm9o9I3" title="Weighted-Average Remaining Life (Years) Outstanding">3.44</td><td style="text-align: left">*</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zl4wZbiVtIp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">67,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTGxXeWaRxZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">1.90</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_iE_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zjIsVEQwOA62" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iE_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zhLvfU6zhkoe" title="Range of Exercise Price, Exercisable">7.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____z1QgQ0JcH8K1" title="Weighted-Average Remaining Life (Years) Exercisable">3.44</td><td style="text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 6pt; text-align: right">*</td> <td style="width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt; text-align: justify">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z4PCv3b752B2" title="Warrants with no expiration">51,199 pre-funded warrants which have no expiration date.</td></tr> </table> The following table summarizes the activity in liability classified warrants for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvmbpeKK1eg9" style="text-align: right; width: 11%" title="Number of Shares, Warrants Outstanding Beginning">68,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkJTLUKjOkzf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> $<span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdX5NwadUane" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zzxUf9YTs7be" title="Range of Exercise Price, Beginning">7.80 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zRVGS0cZDxhc" title="Weighted - Average Remaining Life (Years) Outstanding">4.32</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhhpsv5TEzz2" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZiQ46KhcxK4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceGranted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbft3hhFmeva" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVjhb94oC7Fh" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRNZ9wHbvxl7" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExcercised_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfxLBJUIZBnf" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfDvjXIECGYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNOElKViG8A8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--RangeOfExpiredPrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIfnEwtBiiNc" title="Range of Expired Price">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total outstanding –March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDe1C4QH6o4a" style="border-bottom: Black 2.5pt double; text-align: right">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrQKOEgdTvd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> $<span id="xdx_908_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdZ94WBJOcwa" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zccuZyJ0Shhi" title="Range of Exercise Price, Ending">7.80 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z38HFbkKhop9" title="Weighted-Average Remaining Life (Years) Outstanding">4.07</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcqnPTLBHWY9" style="border-bottom: Black 2.5pt double; text-align: right">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUSpsgom5cX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zLFIJJOSWzvh" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zh0wsz3GvmM6" title="Range of Exercise Price, Exercisable">7.80 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LrM6MA8XKf" title="Weighted-Average Remaining Life (Years) Exercisable">4.07</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td id="xdx_F0E_zkIcdQwk2uCf" style="text-align: right; width: 0.25in">*</td> <td style="width: 0.1in"> </td> <td id="xdx_F13_zYlXj4sXhahe">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zCVO2v8TtDac">51,199 pre-funded warrants which have no expiration date.</td></tr> </table> <p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zZPAZFQqoLFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of March 31, 2026: SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvmETSsj2tl7" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBx745Vkvar2"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLuwPSzmNXec"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zmw49QD2vjQl"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant Liabilities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z7ngVfydpkU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">141,878</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">141,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_z66BP2KqlPcb" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_z5SVTWGwnai7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zAm0AqU8Z0Ll" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on change in fair value of warrant liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,660</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,660</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ziMCexXYTXF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td></tr> </table> The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zja31tZ5Lmlf" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHHUyRrTTI4c"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0NsQsKX4fb3"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20251231_zrLJRpCU08Pl"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zR0ITk2dOta7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zbJvCcQFHDY3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">269,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">269,175</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zHC0CNx9S5wc" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_zDfzNYYrAss6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zrUEfXyBGIdl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on change in fair value of warrant liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ztGd2gSXkxLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2025</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_znqzRouqQHAh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td></tr> </table> There were no transfers of financial assets or liabilities between category levels for the three months ended March 31, 2026 or the year ended December 31, 2025. The value of the warrant liabilities was based on valuations internally generated Black Scholes valuations. Due to the nominal exercise price of the 2024 Pre-Funded Warrants and indefinite term, the Company calculated an implied value of the 2024 Pre-Funded Warrants based on the underlying common stock price on the valuation date, less the exercise price. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements. <p id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zJdhITE4KaS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of March 31, 2026 and 2025: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEjZreM1xsLi" title="Risk-free interest rate">3.87</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zZBQohrytEMj" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfPdqgh8axgh" title="Risk-free interest rate">3.96% - <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zovrBgvhan5i" title="Risk-free interest rate">4.35</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_ziukMdjeiOJc" title="Risk-free interest rate">4.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (peer group)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zfkCp6JfLxlf" title="Expected volatility">130.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpNJiEeewEzd" title="Risk-free interest rate">117.5% -<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcC6jcBCyyR2" title="Risk-free interest rate">133.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_z06IMKeqdGNb" title="Expected volatility">113.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term of warrants (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zK3rxnANWZ0h" title="Term of warrants (in years)">3.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z1vK2Gd3rjz2" title="Warrants outstanding, measurement input">0.14 - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zdgHXG6USn1b" title="Warrants outstanding, measurement input">4.44 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zT6oyrjH76w9" title="Term of warrants (in years)">4.32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXmbf9VQpLjd" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zdgULODrVYQ6" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3xwOEEvP7Db" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zscg9u8JC564" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

68712

2.00

0.05

51199

-69660 -39224

72218

141878

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDfXm3tIKiP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the activity in liability classified warrants for the three months ended March 31, 2026: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLEUWvzhsfse" style="width: 11%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">67,218</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zeHZgZK7Idxg" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1.90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> $<span id="xdx_90E_ecustom--RangeOfExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zlWZfCfox879" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zhiKISKuqd92" title="Range of Exercise Price, Beginning">7.80 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zDDPwKumSIf3" title="Weighted - Average Remaining Life (Years) Outstanding">3.68</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zq4lzljHIxu4" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbMkcW1idpT4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceGranted_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zYcbbKt3xhKl" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMUpruAwPU" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMRyQCDP7Vq1" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceExcercised_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzkvIUXJLg12" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Reclassified from equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedFromEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zlaRUjDD3Fs1" style="text-align: right" title="Number of Shares, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedEquityPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zFcaYHcmbrNh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceReclassifiedFromEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt1wDF7HzDnf" title="Range of Exercise Price, Reclassified from equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToEquity_iN_pid_di_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zEMgsPCqOoe4" style="text-align: right" title="Number of Shares, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageReclassifiedToEquityPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zul9LLUXM4X5" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--RangeOfExercisePriceReclassifiedToEquity_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zyyNJJidcJcf" title="Range of Exercise Price, Reclassified to equity">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRC93G9DQYFh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zxBdI09Kd9Vb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_ecustom--RangeOfExpiredPrice_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zJvvjUYDEgX7" title="Range of Expired Price">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total outstanding –March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zXD8bRG6dnOa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">67,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPtySWmTmnt4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.90</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zGExJ2eKyrD" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_z3e7wwuQvU23" title="Range of Exercise Price, Ending">7.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zNNxUtm9o9I3" title="Weighted-Average Remaining Life (Years) Outstanding">3.44</td><td style="text-align: left">*</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zl4wZbiVtIp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">67,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zTGxXeWaRxZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">1.90</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_iE_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zjIsVEQwOA62" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iE_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zhLvfU6zhkoe" title="Range of Exercise Price, Exercisable">7.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____z1QgQ0JcH8K1" title="Weighted-Average Remaining Life (Years) Exercisable">3.44</td><td style="text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-bottom: 6pt; text-align: right">*</td> <td style="width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 6pt; text-align: justify">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_z4PCv3b752B2" title="Warrants with no expiration">51,199 pre-funded warrants which have no expiration date.</td></tr> </table> The following table summarizes the activity in liability classified warrants for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrants </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding –December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvmbpeKK1eg9" style="text-align: right; width: 11%" title="Number of Shares, Warrants Outstanding Beginning">68,712</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zkJTLUKjOkzf" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">2.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> $<span id="xdx_90B_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdX5NwadUane" title="Range of Exercise Price, Beginning">0.05 - $<span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zzxUf9YTs7be" title="Range of Exercise Price, Beginning">7.80 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_fKg_____zRVGS0cZDxhc" title="Weighted - Average Remaining Life (Years) Outstanding">4.32</td><td style="width: 1%; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhhpsv5TEzz2" style="text-align: right" title="Number of Shares, Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZiQ46KhcxK4" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceGranted_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbft3hhFmeva" title="Range of Exercise Price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVjhb94oC7Fh" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRNZ9wHbvxl7" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--RangeOfExercisePriceExcercised_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfxLBJUIZBnf" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfDvjXIECGYd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zNOElKViG8A8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--RangeOfExpiredPrice_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIfnEwtBiiNc" title="Range of Expired Price">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Total outstanding –March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zDe1C4QH6o4a" style="border-bottom: Black 2.5pt double; text-align: right">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrQKOEgdTvd9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> $<span id="xdx_908_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zdZ94WBJOcwa" title="Range of Exercise Price, Ending">0.05 - $<span id="xdx_90F_ecustom--RangeOfExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zccuZyJ0Shhi" title="Range of Exercise Price, Ending">7.80 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z38HFbkKhop9" title="Weighted-Average Remaining Life (Years) Outstanding">4.07</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcqnPTLBHWY9" style="border-bottom: Black 2.5pt double; text-align: right">68,712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUSpsgom5cX3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercisable">2.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zLFIJJOSWzvh" title="Range of Exercise Price, Exercisable">0.05 - $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iE_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zh0wsz3GvmM6" title="Range of Exercise Price, Exercisable">7.80 </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1LrM6MA8XKf" title="Weighted-Average Remaining Life (Years) Exercisable">4.07</td><td style="padding-bottom: 2.5pt; text-align: left">*</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td id="xdx_F0E_zkIcdQwk2uCf" style="text-align: right; width: 0.25in">*</td> <td style="width: 0.1in"> </td> <td id="xdx_F13_zYlXj4sXhahe">excludes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFdBUlJBTlRTIEFDVElWSVRZIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantsMember_zCVO2v8TtDac">51,199 pre-funded warrants which have no expiration date.</td></tr> </table>

67218

1.90 0.05 7.80 P3Y8M4D

67218

1.90 0.05 7.80 P3Y5M8D 67218 1.90 0.05 7.80 P3Y5M8D

51199

68712

2.00 0.05 7.80 P4Y3M25D

68712

2.00 0.05 7.80 P4Y25D 68712 2.00 0.05 7.80 P4Y25D

51199

<p id="xdx_89A_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zZPAZFQqoLFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of March 31, 2026: SCHEDULE OF FAIR VALUE OF HIERARCHY FOR WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvmETSsj2tl7" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_491_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBx745Vkvar2"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLuwPSzmNXec"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20260101__20260331_zmw49QD2vjQl"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant Liabilities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z7ngVfydpkU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">141,878</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">141,878</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_z66BP2KqlPcb" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_z5SVTWGwnai7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zAm0AqU8Z0Ll" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on change in fair value of warrant liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,660</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(69,660</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ziMCexXYTXF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,218</td><td style="text-align: left"> </td></tr> </table> The following table presents the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis as of December 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zja31tZ5Lmlf" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHHUyRrTTI4c"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20250101__20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0NsQsKX4fb3"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49D_20250101__20251231_zrLJRpCU08Pl"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zR0ITk2dOta7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">269,175</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zbJvCcQFHDY3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">269,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">269,175</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zHC0CNx9S5wc" style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercised_zDfzNYYrAss6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zrUEfXyBGIdl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on change in fair value of warrant liabilities</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(127,297</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_ztGd2gSXkxLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2025</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_znqzRouqQHAh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,878</td><td style="text-align: left"> </td></tr> </table>

141878

-69660

72218

269175

-127297

141878

<p id="xdx_89A_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zJdhITE4KaS9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of March 31, 2026 and 2025: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Range</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">Weighted Average</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zEjZreM1xsLi" title="Risk-free interest rate">3.87</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_zZBQohrytEMj" title="Risk-free interest rate">3.64</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfPdqgh8axgh" title="Risk-free interest rate">3.96% - <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zovrBgvhan5i" title="Risk-free interest rate">4.35</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_ziukMdjeiOJc" title="Risk-free interest rate">4.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility (peer group)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_zfkCp6JfLxlf" title="Expected volatility">130.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zpNJiEeewEzd" title="Risk-free interest rate">117.5% -<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcC6jcBCyyR2" title="Risk-free interest rate">133.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--WeightedAverageMember_z06IMKeqdGNb" title="Expected volatility">113.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Term of warrants (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zK3rxnANWZ0h" title="Term of warrants (in years)">3.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z1vK2Gd3rjz2" title="Warrants outstanding, measurement input">0.14 - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zdgHXG6USn1b" title="Warrants outstanding, measurement input">4.44 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--WeightedAverageMember_zT6oyrjH76w9" title="Term of warrants (in years)">4.32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXmbf9VQpLjd" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zdgULODrVYQ6" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3xwOEEvP7Db" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zscg9u8JC564" title="Warrants outstanding, measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

3.87

3.64

3.96

4.35

4.0

130.0

130.00

117.5

133.5

113.0

P3Y5M8D

P3Y8M4D

P0Y1M20D

P4Y5M8D

P4Y3M25D

0.00

NOTE 9 — CONVERTIBLE DEBT 2025 Convertible Note On April 28, 2025, the Company entered into a Secured Convertible Note (the “2025 Convertible Note”) with Alpha Capital Anstalt (“Alpha”, or “Holder”), pursuant to which the Company issued to Alpha a non-interest-bearing note with a principal of $264,000, and an original issue discount (“OID”) of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zNCcFg7qOG3i" title="Original issue discount">20%, or $44,000, in exchange for $220,000 cash, less $20,000 in expenses. The Note is convertible at any time at Alpha’s option, into shares of the Company’s common stock at a price equal to $3.80 per share, subject to certain adjustments. The Convertible Note bears no interest, and the principal will be due on January 28, 2026 (the “Maturity Date”). The Company determined the 2025 Convertible Note does not contain a substantial premium and therefore the Company elected to account for the Convertible Note under the fair value option in accordance with ASC 825-10-15-4. The Company determined the fair value of the Convertible Note was $<span id="xdx_90D_eus-gaap--ConvertiblePreferredStockConvertedToOtherSecurities_c20250428__20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zWB7HhaKpwr3" title="Fair value of convertible securities">311,943 at issuance. The difference between the $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250428__20250428__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_z5NdYR2BobIk" title="Proceeds from issuance of convertible note">220,000 proceeds received and fair value was recorded as a loss upon issuance in the amount of $91,943. Issuance costs incurred in connection with the transaction were expensed immediately. On June 4, 2025 the Company paid down $132,000 in principal at the request of Alpha, and on January 28, 2026 the remaining balance of $132,000 was paid. As of March 31, 2026, the remaining balance was zero, with a gain on the change in fair value of $<span id="xdx_902_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_za2L3Rmx8dwh" title="Gain loss on extinguishment of debt">10,236 recorded in the three months ended March 31, 2026. As of December 31, 2025 the Company reassessed the fair value of the 2025 Convertible Note at $<span id="xdx_903_ecustom--ChangeInFairValueOfConvertibleNote_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_zLD1CWvfTA5c" title="Change in fair value of convertible note">142,236, with a gain on the change in fair value of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--TwoThounsandTwentyFiveConvertibleNoteMember_z4vLyVXUrrxk" title="Gain loss on extinguishment of debt">37,707 recorded in the year ended December 31, 2025.

264000

0.20

44000

220000

20000

3.80

311943

220000

91943

132000

10236

142236

37707

NOTE 10 — PROMISSORY NOTES During the year ended December 31, 2025, the Company issued short term notes payable totaling $4.4 million for total net proceeds of $3.4 million. Over the course of the year the Company repaid all notes for a total of $4.4 million, with the additional $1.0 million paid as a premium to some of the lenders and was recorded under interest expenses. There were no outstanding promissory notes outstanding as of March 31, 2026 or December 31, 2025.

4400000

3400000

4400000

1000000.0

NOTE 11 — LOSS PER SHARE <p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zB4FpdCOsLic" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Basic loss per share (“EPS”) is computed by dividing net loss including deemed dividends by the weighted-average number of common shares outstanding plus unexercised pre-funded warrants. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from preferred stock, convertible debt, stock options and warrants. SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_z5hCuILNleV4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zHJjj36FA7Vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfitLoss_zyYsTeOeStIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net loss used for basic earnings per share</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(6,079,016</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(2,646,172</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zhhRDnwCMsZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,704,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,456,714</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zK5J4YYvDcZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zNKtd0x4eWz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted weighted-average common shares outstanding</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,704,597</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,456,714</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zo8HhX1TsVrb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">These potentially dilutive securities have been excluded from diluted net loss per share as of March 31, 2026 and 2025 because their effect would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_ztdHDpHfsPN1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zTOnU0EHs0w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zpH2CG79U5e5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zt7n4OUeYTZ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of common stock subject to outstanding warrants (excluding pre-funded warrants)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528,371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zOcX1hQWEaAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of common stock subject to outstanding preferred stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,976,848</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,659,615</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zBJIJhgh6Rr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total common stock equivalents</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,505,219</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,750,866</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zB4FpdCOsLic" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Basic loss per share (“EPS”) is computed by dividing net loss including deemed dividends by the weighted-average number of common shares outstanding plus unexercised pre-funded warrants. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from preferred stock, convertible debt, stock options and warrants. SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_z5hCuILNleV4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zHJjj36FA7Vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfitLoss_zyYsTeOeStIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net loss used for basic earnings per share</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(6,079,016</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(2,646,172</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zhhRDnwCMsZ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,704,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,456,714</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zK5J4YYvDcZ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dilutive potential shares issuable from preferred stock, convertible debt, stock options and warrants</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zNKtd0x4eWz7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Diluted weighted-average common shares outstanding</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,704,597</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,456,714</td><td style="text-align: left"> </td></tr> </table>

-6079016

-2646172

7704597

1456714

7704597

1456714

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zo8HhX1TsVrb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">These potentially dilutive securities have been excluded from diluted net loss per share as of March 31, 2026 and 2025 because their effect would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260101__20260331_ztdHDpHfsPN1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zTOnU0EHs0w2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zpH2CG79U5e5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares of common stock subject to outstanding options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,570</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zt7n4OUeYTZ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of common stock subject to outstanding warrants (excluding pre-funded warrants)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528,371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_zOcX1hQWEaAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of common stock subject to outstanding preferred stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,976,848</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,659,615</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zBJIJhgh6Rr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total common stock equivalents</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,505,219</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,750,866</td><td style="text-align: left"> </td></tr> </table>

1570

528371

89681

2976848

1659615

3505219

1750866

<p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMK1WReN5dS7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 12 — COMMITMENTS AND CONTINGENCIES As of March 31, 2026, the Company has no commitments and contingencies.

<p id="xdx_80E_ecustom--ResearchAndLicenseAgreementsTextBlock_zkSURXDhE2sd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in">NOTE 13 — RESEARCH AND LICENSE AGREEMENTS UCL Business Limited In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at the Company under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required a $<span id="xdx_90F_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zQcaD68D3A8l" title="Reimbursement of patent">150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to the Company. There were no license costs recorded related to this agreement during the three months ended March 31, 2026 and 2025. QN-302 Phase 1 Study In June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (“TD2”) whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company may enter into statements of work with TD2 for the performance of specific services under this Master Clinical Research Services Agreement. In June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) whereby MLM agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply, testing, validation, data management, and storage services. From time to time, the Company may enter into work orders with MLM for the performance of specific services under this Master Laboratory Services Agreement. In June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (“Clinigen”) whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company may enter into statements of work with Clinigen for the performance of specific services under this Master Services Agreement. In July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services for the conduct of the QN-302 Phase 1 study. Given our financial situation, the company slowed the development of the QN-302 Phase 1 Study beginning in the second quarter of 2024. University of Louisville Research Foundation In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville Research Foundation, Inc. (“ULRF”) for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $<span id="xdx_902_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z0ge7sdzya5h" title="Reimbursement of research expenses">693,000 for this program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement expired in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately $<span id="xdx_903_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zvuKz85GZdt7" title="Research expenses">2.9 million. <span id="xdx_90C_ecustom--AgreementTermPaymentDescription_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zhLD6BIGWeSb" title="Agreement term payment, description">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $<span id="xdx_907_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zBgN3AxPoUge" title="Milestone payment">50,000 to $<span id="xdx_906_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z5xoiBAdyeaa" title="Milestone payment">5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $<span id="xdx_90B_ecustom--MilestonePayment_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zBEfQtiVlgfh" title="Milestone payment">50,000 for first dosing in a Phase 1 clinical trial, $<span id="xdx_906_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zx572P0J21x3" title="Milestone payment">100,000 for first dosing in a Phase 2 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zbgDxhapJooh" title="Milestone payment">150,000 for first dosing in a Phase 3 clinical trial, $<span id="xdx_90F_ecustom--CumulativeSalesOne_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zpT7mViWlMti" title="Cumulative sales">300,000 for regulatory marketing approval and $<span id="xdx_900_ecustom--CumulativeSales_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zHCyYWLh04Kg" title="Cumulative sales">5,000,000 upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zDqToiszaxl8" title="Revenue">500,000,000 of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLoQTJ4merjh" title="Upfront license fee">20,000 to $<span id="xdx_900_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zhIHagFLzSy9" title="Upfront license fee">100,000) for such year. There were <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_do_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zeiuHeeNdHFl" title="Research and development expenses"><span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOs1B8wj5X9i" title="Research and development expenses">no sponsored research expenses or license costs related to these agreements for the three months ended March 31, 2026 and 2025. Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. <span id="xdx_90B_ecustom--AgreementTermPaymentDescription_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zP6Rg9tEftc4" title="License and sponsored research agreement terms">Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z1URvcDhOM4d" title="Proceeds from convertible debt">50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $<span id="xdx_905_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zjJqxHptYZkb" title="Reimbursement of research expenses">805,000 and prior patent costs of up to $<span id="xdx_902_ecustom--PatentCosts_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z4BC9ogdsdq7" title="Patent costs">200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zvHaTnv9z8g8" title="Milestone payment">100,000 to $<span id="xdx_903_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGwNYNTjmV03" title="Milestone payment">5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z2emuDCg4lJg" title="Milestone payment">100,000 for first dosing in a Phase 1 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLXMK32Upyg9" title="Milestone payment">200,000 for first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zZGxWJdasZAl" title="Milestone payment">350,000 for first dosing in a Phase 3 clinical trial, $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z7T7Y6k5W2M7" title="Marketing approval expenses">500,000 for regulatory marketing approval and $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zC2gIITMbLm5" title="Cumulative sales">5,000,000 upon achieving a cumulative $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zKWYzpi3p2z8" title="Revenue">500,000,000 of Licensed Product sales. The Company also agreed to pay another $<span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zV1gOatovfvl" title="Regulatory marketing approval, expenses">500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_901_ecustom--ShortfallPayments_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zbp7yubl53o3" title="Shortfall payments">10,000 to $<span id="xdx_905_ecustom--ShortfallPayments_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zt4VGAS7PWqf" title="Shortfall payments">50,000) for such year. The sponsored research agreement for QN-247 expired in August 2022 and there were <span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_do_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zvy48drroVbg" title="Research and development expenses"><span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_do_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember_zesniHNu5YC7" title="Research and development expenses">no sponsored research expenses or license costs related to these agreements for the three months ended March 31, 2026 and 2025. All agreements with the ULRF were terminated in August 2024. Marizyme On April 11, 2024, we entered into a Co-Development Agreement with Marizyme. Under the Co-Development Agreement (as amended), <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_c20240411__20240411__us-gaap--TypeOfArrangementAxis__custom--CoDevelopmentAgreementMember_zfL8eWSzRNK8" title="Marizyme agreement terms">we agreed to pay Marizyme funding payments and an exclusivity fee of $200,000. The Exclusivity Fee of $200,000 and a funding payment of $500,000 was paid to Marizyme on April 12, 2024, and is included in research and development expenses in the unaudited condensed consolidated statements of operations and other comprehensive loss. The Exclusivity Fee entitled us to an exclusivity period until May 31, 2024 for purposes of proposing and outlining a broader strategic relationship with Marizyme with regard to Marizyme’s DuraGraft business. The funding payments are designed to provide financial support for commercialization of Marizyme’s DuraGraft™ vascular conduit solution, which is indicated for adult patients undergoing coronary artery bypass grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in coronary artery bypass grafting surgery. In return for the funding payments we will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the funding payments provided. No such payments-in-the-nature-of-royalties would accrue until after DuraGraft has been launched in the United States and a cumulative total of $500,000 of DuraGraft Net Sales have been made in the United States. As of the March 31, 2026, these conditions have not been met and no royalty payments are due. 150000 160000 0 0 693000 2900000 In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. 50000 5000000 50000 100000 150000 300000 5000000

500000000

20000 100000

Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $805,000 and prior patent costs of up to $200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company also agreed to pay another $500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $10,000 to $50,000) for such year.

50000

805000 200000 100000 5000000 100000 200000 350000 500000 5000000

500000000

500000 10000 50000

we agreed to pay Marizyme funding payments and an exclusivity fee of $200,000. The Exclusivity Fee of $200,000 and a funding payment of $500,000 was paid to Marizyme on April 12, 2024, and is included in research and development expenses in the unaudited condensed consolidated statements of operations and other comprehensive loss. The Exclusivity Fee entitled us to an exclusivity period until May 31, 2024 for purposes of proposing and outlining a broader strategic relationship with Marizyme with regard to Marizyme’s DuraGraft business. The funding payments are designed to provide financial support for commercialization of Marizyme’s DuraGraft™ vascular conduit solution, which is indicated for adult patients undergoing coronary artery bypass grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in coronary artery bypass grafting surgery. In return for the funding payments we will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the funding payments provided. No such payments-in-the-nature-of-royalties would accrue until after DuraGraft has been launched in the United States and a cumulative total of $500,000 of DuraGraft Net Sales have been made in the United States. As of the March 31, 2026, these conditions have not been met and no royalty payments are due.

200000

500000

NOTE 14 — STOCKHOLDERS’ EQUITY As of March 31, 2026 and 2025, the Company had two classes of authorized capital stock: common stock and preferred stock. Common Stock Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions. At March 31, 2026, the Company has reserved 4,203,443 shares of authorized but unissued common stock for possible future issuance as follows: <p id="xdx_898_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zXeIBIs97Bd5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF RESERVED SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_494_20260331_zcwO47I6B5Li" style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zd142fVHJz21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of Series A-2 preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">267,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zDZ7AfmNZPgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Series B preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,709,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrahJAXGn0Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of stock warrants</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,226,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zb35soaI6LT6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,203,443</td><td style="text-align: left"> </td></tr> </table> Faraday Subscription Agreement As described in Note 1 – Business and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, the Company consummated the Subscription Agreement with certain investors, including Faraday pursuant to which the Company issued and sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zWErddIdGIha" title="Number of shares issued and sold">337,432 shares of the Company’s common stock and issued <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LegalFirmMember_zVqDxVOccd95" title="Number of shares issued and sold">100,000 to the Company’s legal firm . The purchase price of the common stock was $2.246 per share for an aggregate $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_z2nXplVSDkQg" title="Value of shares sold">0.8 million. Additionally, in connection with the closing of the Subscription Agreement, the Company issued <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvisorMember_zqWV4Mq2mMg5" title="Number of shares issued and sold">60,257 shares of common stock as compensation to its advisor which has been accounted for under ASC 718 Compensation—Stock Compensation (See Note 1 – Organization and Summary of Significant Accounting Policies and Estimates). Further, in connection with the closing of the Subscription Agreement, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zQtpmffzMKi8" title="Warrants issued">1,087,266 warrants were issued to the placement agent, (the “Placement Agent Warrants”). The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250929__us-gaap--TypeOfArrangementAxis__custom--FaradaySubscriptionAgreementMember_zZmVR8TPKz9g" title="Exercise price">2.47 per share. At March 31, 2026, 1,087,266 Placement Agent Warrants remain outstanding. 2024 Common Stock Purchase Agreement On November 19, 2024, the Company entered into a Common Stock Purchase Agreement (the “Common Stock Purchase Agreement”) with Horberg Enterprises LP (the “Investor”), pursuant to which the Company in its sole discretion has the right, but not the obligation, to issue and sell to the Investor up to $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20241119__20241119__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zCB4pVbXl9Ze" title="Value of shares available for sale">10.0 million of the Company’s common stock, from time to time beginning on the Commencement Date, as discussed below, subject to certain limitations and conditions detailed in the Common Stock Purchase Agreement. The Company is not obligated to sell any shares to the Investor under the Common Stock Purchase Agreement; sales and timing of any sales of the Company’s common stock are solely at the Company’s election. In accordance with the terms of the Common Stock Purchase Agreement, the Commencement Date is subject to certain conditions, including the effectiveness of a registration statement on Form S-1 or a similar prospectus permitting the Investor to offer and resell the shares of common stock acquired under the Common Stock Purchase Agreement. No upfront fees were paid to the Investor at the execution of the arrangement. As of March 31, 2025, no registration statement had been filed and thus the Commencement Date permitting the sale of shares under the Common Stock Purchase Agreement had not yet occurred. The Company evaluated the Common Stock Purchase Agreement under ASC 815-40 Derivatives and Hedging-Contracts on an Entity’s Own Equity as it represents the right to require the Investor to purchase shares of Common Stock in the future, similar to a put option. The Company concluded the Common Stock Purchase Agreement represents a freestanding derivative instrument that does not qualify for equity classification and therefore requires fair value accounting. The Company analyzed the terms of the contract and concluded the derivative instrument had no value at inception, as of March 31, 2026, or as of December 31, 2025. Preferred Stock There are a total of 15,000,000 shares of Preferred Stock authorized, of which <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zXGJeKQ4JBri" title="Preferred stock, shares designated">7,000 shares are designated as Series A-2 Preferred Stock, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zFHzISinZnu5" title="Preferred stock, shares designated">10,000 shares are designed as Series A-3 Preferred Stock, and to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxS0Uu9AiCwk" title="Preferred stock, shares designated">500,000 shares are designated as Series B Preferred Stock. As described in Note 1 – Organization and Summary of Significant Accounting Policies and Estimates, on September 29, 2025, the Company consummated the Subscription Agreement pursuant to which the Company issued <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250929__20250929__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zRlypmmGfmne" title="Number of shares issued and sold">39,943 shares of the newly designated Series B Preferred Stock, for $1,000 per share, for aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250929__20250929__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zt7qahktjA95" title="Gross proceeds from issuance of shares">39.9 million, before deducting placement agent fees and other offering expenses. This offering triggered a down-round provision of the Series A-2 Convertible Preferred Stock and Series A-3 Convertible Preferred Stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $2.0 million deemed dividend in the amount equal to the change in fair value of the abovementioned series of convertible preferred stock before and after the anti-dilution adjustment. On July 28, 2025, in a private placement transaction, the Company sold and issued to certain institutional and accredited investors <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250728__20250728__us-gaap--AwardTypeAxis__custom--SeriesA3ConvertiblePreferredStockMember_zwmFqS3OIuBb" title="Number of shares issued and sold">4,500 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share, (the “Series A-3 Preferred Stock”), at a purchase price of $1,000 per share, for aggregate gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20250728__20250728__us-gaap--AwardTypeAxis__custom--SeriesA3ConvertiblePreferredStockMember_zgbe76Cq3Rbb" title="Gross proceeds from issuance of shares">4.5 million before deducting placement agent fees and offering expenses of $0.2 million, resulting in net proceeds of $4.3 million. This offering triggered a down-round provision of the Series A-2 Convertible Preferred stock, as described further below, which resulted in a lower conversion price. As a result, the Company recorded a $0.6 million deemed dividend in the amount equal to the change in fair value of the aforementioned series of convertible preferred stock before and after the anti-dilution adjustment. On November 20, 2024 in a private placement transaction, the Company sold and issued to certain institutional and accredited investors <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241120__20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zAHtI43GwbIk" title="Number of shares issued and sold">5,102 shares of the newly designated Series A-2 Convertible Preferred Stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zpXeeYEEV4s" title="Preferred stock, par value">0.001 per share (the “Series A-2 Preferred Stock” and together with the Series A-3 Preferred Stock, the “Series A Preferred Stock”), at a purchase price of $1,000 per share, for an aggregate purchase price of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20241120__20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zkgvUUdMPaf8" title="Gross proceeds from issuance of shares">5.1 million. The Company also entered into an Exchange Agreement with Yi Hua Chen on November 18, 2024, pursuant to which it issued <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pp0p0_c20241118__20241118__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zQZXorpOPeV9" title="Shares issued upon debt exchange">1,154 shares of Series A-2 Preferred Stock in full settlement of the outstanding balance of the 2024 Chen Debenture of approximately $<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_pn4n6_c20241118__20241118__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zNbNNACiJsfc" title="Debt amount exchanged">1.15 million. During the year ended December 31, 2025, <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_z6EoOAV0b8vb" title="Preferred stock, shares outstanding">5,656 shares of Series A-2 Convertible Preferred stock and <span id="xdx_900_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zo93iUMOIrf8" title="Common shares issuable upon conversion">4,500 shares of Series A-3 Convertible Preferred Stock were converted into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zr9eItbPzJ53" title="Preferred stock converted">3,926,263 shares of common stock at a Conversion Price ranging from $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2AndA3ConvertiblePreferredStockMember__srt--RangeAxis__srt--MaximumMember_zEy1zsVYt6dg" title="Conversion price">3.64 to $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesA2AndA3ConvertiblePreferredStockMember__srt--RangeAxis__srt--MinimumMember_zQr7cI9mjzbe" title="Conversion price">2.246. During the three months ended March 31, 2026, <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zVUWQDMxgd49" title="Preferred stock, shares outstanding">33,858 shares of Series B Convertible Preferred Stock were converted into <span id="xdx_906_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zlqeu67q10rg" title="Common shares issuable upon conversion">15,074,610 shares of common stock at a Conversion Price of $2.246. At March 31, 2026, the Company’s outstanding preferred stock consists of the following: SCHEDULE OF OUTSTANDING PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Authorized Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Equivalent</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%">Series A-2</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zzqTAaUYPBc1" style="width: 11%; text-align: right" title="Preferred stock, shares authorized">7,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zDlYqjS2Ald7" style="width: 11%; text-align: right" title="Preferred stock, shares outstanding">601</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zw3lAHq7vtqi" style="width: 11%; text-align: right" title="Preferred stock, conversion price">2.246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zdZPL2drFIPj" style="width: 11%; text-align: right" title="Preferred stock, common stock equivalent">267,587</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zqyUyA3sZUO8" style="text-align: right" title="Preferred stock, shares authorized">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zO4dKv05xC6i" style="text-align: right" title="Preferred stock, shares outstanding">6,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zMUczSjHGiKj" style="text-align: right" title="Preferred stock, conversion price">2.246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zJ0nahX33qk9" style="text-align: right" title="Preferred stock, common stock equivalent">2,709,261</td><td style="text-align: left"> </td></tr> </table> The shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock have the rights, preferences, powers, restrictions and limitations as set forth below. Conversion Rights – Each share of Preferred Stock is convertible at any time, at the option of the holder, into a number of shares of common stock equal to $1,000 (the “Stated Value”), divided by a conversion price initially equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA2ConvertiblePreferredStockMember_zEKRwDElx2n9" title="Conversion price, per share">3.64 for each share of Series A-2 Preferred Stock, $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesA3ConvertiblePreferredStockMember_zuD5T6UG3AC" title="Conversion price, per share">2.80 for each share of Series A-3 Preferred stock and $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241120__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdKUUCZ5FT3l" title="Conversion price, per share">2.246 for each share of Series B Preferred Stock (the “Conversion Shares”), subject to adjustment for any stock splits, stock dividends and similar events (the “Conversion Price”). The Conversion Prices of the Series A Preferred Stock are also subject to down-round adjustments if the Company at any time while the Series A Preferred Stock is outstanding issues common stock or common stock equivalents at a lower effective price per share than the then-effective Conversion Price, in all cases subject to a floor price of $1.82 and $1.40 for the Series A-2 Preferred Stocka and the Series A-3 Preferred Stock, respectively. Conversion of the Series A Preferred Stock will be prohibited if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 4.99% (or 9.99% at the option of the holder) of the total number of shares of the Company’s common stock issued and outstanding. Liquidation Preference – Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, the holders of Series A Preferred Stock shall be entitled to an amount equal to the Stated Value for each share of Series A-2 Preferred Stock before any distribution or payment shall be made to the holders of common stock. Upon any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, the holders of Series B Preferred Stock shall be entitled to an amount equal to the Stated Value, plus any accrued and unpaid dividends thereon before any distribution or payment shall be made to the holders of common stock. Voting Rights – The holders of Series A Preferred Stock are entitled to vote, together as a single class with the common stock, on all matters presented to the common stockholders for a vote. Each share of Preferred Stock is entitled to a number of votes equal to the number of shares into which such share of Preferred Stock would be convertible, as of the record date for determination of stockholders entitled to vote as to such matter, if the conversion price was equal to the “Minimum Price” (as defined in Nasdaq Listing Rule 5635(d)) as of the original issue date of the Series A Preferred Stock, taking into account for such purposes the beneficial ownership limitation as then in effect. The holders of Series B Preferred stock will vote together with common stock on an as-converted basis. Dividends – The holders of Series A Preferred Stock and Series B Preferred Stock are entitled to receive dividends, if and when such dividends are paid to holders of common stock, in the same form and at the same time on an as-converted to common stock basis. Protective Provisions – At all times while the Series A Preferred Stock and Series B Preferred Stock are outstanding, without the consent of the holders of at least 67% of the Stated Value of each series of the then-outstanding Series A Preferred Stock and holders of at least 75% of the Stated Value of the then-outstanding Series B Preferred Stock, (the “Required Consent”), the Company is prohibited from amending its charter documents in any manner that adversely affects the rights of the Series A Preferred Stock and Series B Preferred Stock, repurchase junior securities of the Company, pay cash dividends or distributions on junior securities of the Company, or enter into a material transactions with an affiliate of the Company (unless it is at arm’s length and expressly approved by a majority of the disinterested directors). Without the Required Consent of the Series B Preferred Stock, the Company is prohibited from entering into, creating, assuming or guaranteeing any new indebtedness or liens of any kind. In addition, as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock directly and/or indirectly (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise pari passu with, the Series B Preferred Stock or, authorize or create any class of stock ranking as to dividends senior to, or otherwise pari passu with, the Series B Preferred Stock, (c) amend its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of the Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, or (e) enter into any agreement with respect to any of the foregoing. Upon any subsequent issuance by the Company or any of its subsidiaries of common stock or common stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), holders of Series B Preferred Stock may elect, in its sole discretion, to exchange (in lieu of conversion), if applicable, all or some of the shares of Series B Preferred Stock then held for any securities or units issued in a Subsequent Financing on a $1.00 for $1.00 basis. Additionally, if in such Subsequent Financing there are any contractual provisions or side letters that provide terms more favorable to the investors than the terms previously provided to holders of the Series B Preferred Stock, holders of the Series B Preferred Stock shall become a part of the transaction documents, at their option. Stock Options and Warrants Stock Options The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period. In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. In October 2025, the Company adopted the 2025 Equity Incentive Plan (the “2025 Plan”), which provides for the granting of incentive or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service providers. As of March 31, 2026, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_do_c20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyFiveStockIncentivePlanMember_z7pXIKMK5wo9" title="Options outstanding">no awards were granted or outstanding under the 2025 Plan. Equity Classified Compensatory Warrants As part of the May 2020 reverse recapitalization transaction, the Company issued equity classified compensatory common stock warrants to an advisor and its designees. In addition, various service providers hold equity classified compensatory common stock warrants issued in 2017 and earlier (originally exercisable to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock). These are to be differentiated from the Series C Warrants described in Note 8 - Warrant Liabilities. As of March 31, 2026, warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbWi06U3jfg4" title="Warrants to purchase common stock">107 shares of the Company’s common stock remain outstanding. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_do_c20260101__20260331_zcDDQ79yWlNf" title="Number of shares, warrants granted">No new compensatory warrants were issued during the three months ended March 31, 2026 or the three months ended March 31, 2026. <p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ERFMhi3Jwd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the equity classified compensatory warrant activity for the three months ended March 31, 2026: SCHEDULE OF COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Total outstanding – December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zd3epEQSJPmi" style="width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">160</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zDPwW6ZYuzPk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLY7lTZmFEaf" title="Range of exercise price - beginning">1,270.25 — $<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zQp224rmLVIh" title="Range of exercise price - beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMK87dSDOzV8" title="Weighted Average Remaining Life (Years) - outstanding">0.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaaea16XhROg" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4X3IuGtbhEe" style="text-align: right" title="Weighted average exercise price per share warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRsyoOqKkGo5" style="text-align: right" title="Number of Shares, Warrants Expired">(53</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOr3Ewa5lpGk" style="text-align: right" title="Weighted average exercise price per share warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zf9XXYL6jsCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrstNWAIPln5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total outstanding – March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQZRgyvb1Shc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">107</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z8IbwlsQ6vTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zpDRbFcqonn3" title="Range of exercise price - ending">1,270.25— $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_ziRq5FjeRCX5" title="Range of exercise price - ending">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm80mgfFqdOb" title="Weighted Average Remaining Life (Years) - outstanding">0.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfPkpeWtDTge" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">107</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhJ0Ae88TCcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfnKS4aiQ9i" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUZWsE1cG7Je" title="Range of exercise price, exercisable">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z97LRCaPiAd8" title="Weighted Average Remaining Life (Years) Exercisable">0.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zym3l0W9GpD5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdrSgNdFz4Ei" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zCH3GX0o6Wd4" title="Range of Exercise Price, Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The following table summarizes the equity classified compensatory warrant activity for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1pNeUJzZIXj" style="width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7GG97dr3Ltj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">$<span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_znGJY2bedBwa" title="Range of exercise price - beginning">1,270.25 — $<span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zhcWdynmXX79" title="Range of exercise price - beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzgnzlrElJQc" title="Weighted Average Remaining Life (Years) - outstanding">0.69</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z42qv1vQnFIb" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z0P3V3jCy8Qj" style="text-align: right" title="Weighted average exercise price per share warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z8cGfwEje8H5" style="text-align: right" title="Number of Shares, Warrants Expired">(345</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z5cFNu164TO2" style="text-align: right" title="Weighted average exercise price per share warrants expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_909_ecustom--RangeOfExercisePriceExpired_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGMRRuBkDFA" title="Range of Exercise Price, Expired">1,270.25 — $<span id="xdx_907_ecustom--RangeOfExercisePriceExpired_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z4xdnioRQ1Yb" title="Range of Exercise Price, Expired">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zuHMznqITKG8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsLHu0eiHBec" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total outstanding – March 31, 2025</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zkWNpf4Xh20k" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">164</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7PZQRQr5Nyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,265.45</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_900_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zpNvGgXzzTLk" title="Range of exercise price - ending">1,270.25 — $<span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zJSIpyYiViak" title="Range of exercise price - ending">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z04exlbnMTwb" title="Weighted Average Remaining Life (Years) - outstanding">1.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zv65A8nfHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">164</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zIzB4AioeqHi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,265.45</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zAeBSpLzg5Ya" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zsDXx5WQUz3f" title="Range of exercise price, exercisable">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zKeAQs0Xdjd1" title="Weighted Average Remaining Life (Years) Exercisable">1.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAuJ6P6siUpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoLmuQgx5EEa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQmOyG9h2yM" title="Range of Exercise Price, Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table> There were no compensation costs related to outstanding warrants for the three months ended March 31, 2026 and 2025. As of March 31, 2026 and 2025, there was <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zCfPVqgPdUFi" title="Unrecognized compensation cost"><span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20250331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4xaYEf9xP1c" title="Unrecognized compensation cost">no unrecognized compensation cost related to nonvested warrants. Noncompensatory Equity Classified Warrants On December 22, 2022, in conjunction with the issuance of a debenture to Alpha (see Note 9 – Convertible Debt), the Company issued to Alpha a warrant to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zP3tZKq3PO85" title="Warrant to purchase shares">50,000 shares of the Company’s common stock. The exercise price of this warrant was initially $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zZMKrJsMlh89" title="Exercise price of warrant">82.50, and may be exercised in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to the related Securities Purchase Agreement, with Alpha. This Amendment reduced the Exercise Price of the December 22, 2022 warrant from $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zwMm8Ui6rhtk" title="Exercise price of warrant">82.50 per share to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zGzyQcWJsfd" title="Exercise price of warrant">36.50 per share. The Amendment also revised certain provisions of the warrant which resulted in reclassification of the warrant from liabilities to equity during the year ended December 31, 2023. During the year ended December 31, 2024 this warrant was partially exercised for <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z2gxpE5aird1" title="Warrant exercised">31,998 shares, and as of March 31, 2026 warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260331__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z7PKnu0QyZsb" title="Warrant to purchase shares of common stock">18,002 shares of the Company’s common stock remain outstanding. On February 27, 2024 the Company entered into a new Securities Purchase Agreement with Alpha for the purchase of the February 2024 Debenture (see Note 9 – Convertible Debt). This Securities Purchase Agreement resulted in the reduction of the exercise price of the December 22, 2022 warrant and the May 2020 warrant from $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zFb18hvt45wk" title="Exercise price of warrant">36.50 per share to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeqgz9c8sGz8" title="Exercise price of warrant">13.00 per share. The company recognized a deemed dividend of $60,017, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity. In addition, on February 27, 2024, the Company issued to Alpha a warrant to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zTUxN2wl2CAi" title="Warrant to purchase shares of common stock">18,001 shares of the Company’s common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zeOC5dl1r3Kf" title="Exercise price of warrant">13.00 per share, which may be exercised in whole or in part, at any time before February 27, 2029. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zXfsz66p3gS6" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zMwIo2HvAHCc" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited consolidated statements of changes in stockholders’ equity. On April 12, 2024, in connection with the issuance of a convertible debenture to Chen (see Note 9 – Convertible Debt), the Company issued a liability classified warrant to Chen to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_z5wObq2EPBB3" title="Warrant to purchase shares">36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zkTGHfjWrjrg" title="Exercise price of warrant">13.00 per share to an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zfZxPedzTBka" title="Exercise price of warrant">6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of shareholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that shareholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zhplmxpHbYL9" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zTMZDMRPbQvg" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital. As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until shareholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 8 – Warrant Liabilities). Shareholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that shareholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. On September 6, 2024, upon the closing of a public offering, the Company issued pre-funded warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zbIiF4Lj4jJl" title="Warrant to purchase shares of common stock">239,456 common shares at a price of $6.45 per share with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zfxxdjEACud4" title="Warrant exercise price">0.05 per share (the “pre-funded warrants”). The pre-funded warrants are exercisable upon issuance and will remain exercisable until all the pre-funded warrants are exercised in full. Pre-funded warrants for <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPrefundedInvestorWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zhCBMiWmO76f" title="Warrants exercised">188,257 common shares were exercised during the year ended December 31, 2024. At March 31, 2026 pre-funded warrants for 51,199 common shares remained outstanding. On September 6, 2024, upon the closing of a public offering, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240906__20240906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsWRZEdn8St3" title="Number of warrants issued">16,019 warrants were issued to the placement agent. These warrants were not exercisable until March 5, 2025 and expire on September 6, 2029. On November 20, 2024, the Company closed its private placement transaction resulting in the issuance of newly designated Series A-2 Preferred Stock. As a result of the issuance of a new class of voting securities, the Company evaluated its equity classified compensatory warrants’ respective terms, and concluded that compensatory warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zJEnS3W0XwX" title="Warrants reclassified to liabilities">1,353 common shares with a weighted average exercise price of $<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassifiedToLiabilitiesInPeriodWeightedAverageExercisePrice_c20241120__20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zWGjd6PDmQBi" title="Weighted average exercise price per share warrants reclassified to liabilities">6.50 and a fair value of $<span id="xdx_900_ecustom--FairValueOfWarrantsReclassifiedToLiabilitiesFromEquity_c20241120__20241120__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOGWYcB7AmKh" title="Fair value of warrants reclassified to liabilities from equity">904 were required to be reclassified to liabilities as of November 20, 2024. On April 28, 2025 as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note (see Note 9 - Convertible Debt), warrants for <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250428__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z761WxcFpqwa" title="Warrant to purchase shares">54,002 common shares were repriced from $6.50 per share exercise price to $5.82 per share exercise price. The company recognized a deemed dividend of $1,586, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity. As discussed above, on September 29, 2025, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250929__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_z3o455c0mJXc" title="Warrant to purchase shares of common stock">1,087,266 Placement Agent Warrants were issued. The Placement Agent Warrants were immediately exercisable and have an initial exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250929__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zamvU56qjdy8" title="Exercise price">2.47 per share. At March 31, 2026, 1,087,266 Placement Agent Warrants remain outstanding. <p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zOvdSGkpavdj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2026: SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Total outstanding – December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUAdpXmByRh8" style="width: 11%; text-align: right" title="Number of shares, warrants outstanding beginning">1,159,270</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVRQuxd6HyNj" style="width: 11%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">2.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">$<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zi4Ji2mNFdkb" title="Range of exercise price">2.47 — $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlenqPotqzq3" title="Range of exercise price">6.50 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY3woDGRX4m" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGbh3EGC4np3" style="text-align: right" title="Number of shares, warrants outstanding granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zM8YNv8CxzG2" style="text-align: right" title="Weighted average exercise price, warrants granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGa5eOgDuPbb" title="Range of exercise price warrant, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjdDKECdy2L3" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxJLV0baiSnc" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zty1QU1ZHlT4" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIXAlCixEEDb" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGKijhPumQib" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zr1M32WZC6Jf" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhc5D79n6sTg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_ziekdejfEOQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zy9T71BqIMec" title="Range of Exercise Price, Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Total outstanding – March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0YQkvQI1r55" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">1,159,270</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHi4o7mz6Zib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">2.72</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4S2MC3yPiB3" title="Range of exercise price">2.47 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqde0sW1oT2l" title="Range of exercise price">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_znFfLd4DpHmj" title="Weighted average remaining life (Years) exercisable">4.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAIZrlNYosnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,159,270</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zkW87GAYknRc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.72</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z6hiqKVJxnc4" title="Range of exercise price, exercisable">2.47 — $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcBEwuZfTowg" title="Range of exercise price, exercisable">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvsjVEvHBtrk" title="Weighted average remaining life (Years) exercisable">4.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxTIVOPjLrHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zt1d7Fr8tI29" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGfHZAgw2ril" title="Range of exercise price, Non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAmw5OWJUENj" style="width: 11%; text-align: right" title="Number of shares, warrants outstanding beginning">72,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6CAlzgig9uh" style="width: 11%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">$<span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zosh8wRaKZT5" title="Range of exercise price">6.50 — $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zMOgXeDLvYw9" title="Range of exercise price">6.50 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zufNVAiJDvri" title="Weighted average remaining life (Years) exercisable">3.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zYIAXOuvNvI1" style="text-align: right" title="Number of shares, warrants outstanding granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6WYrcEs7mdi" style="text-align: right" title="Weighted average exercise price, warrants granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyOf5FywJcN5" title="Range of exercise price warrant, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRTCmbokoTxc" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd8PQdJhNja8" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zE1WEGjLICQe" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJy0zZT0v2ek" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKZS10HN4qx7" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFg05veyQPwl" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJu9BWPnOVj2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZ3Cd5GSn4Ll" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zqANX2GrWhvj" title="Range of Exercise Price, Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Total outstanding – March 31, 2025</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOVG07JtlyYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">72,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNTcK8by3y86" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">6.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z78zflE97Cic" title="Range of exercise price">6.50 — $<span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zotQnlWPDip2" title="Range of exercise price">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6e5s1lv8aHf" title="Weighted average remaining life (Years) exercisable">3.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZ8wcVs8Xud2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">72,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6Rwp2wrfryb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">6.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z3L3BZ0yCbzl" title="Range of exercise price, exercisable">6.50 — $<span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zzLoOuAP1FTk" title="Range of exercise price, exercisable">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmzPh0ugkyt5" title="Weighted average remaining life (Years) exercisable">3.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zqpVcyVzLja1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVsy5vxXkgyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFSTi3C29lgi" title="Range of exercise price, Non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table>

4203443

<p id="xdx_898_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zXeIBIs97Bd5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF RESERVED SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_494_20260331_zcwO47I6B5Li" style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zd142fVHJz21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Conversion of Series A-2 preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">267,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zDZ7AfmNZPgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Conversion of Series B preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,709,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrahJAXGn0Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercise of stock warrants</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,226,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zb35soaI6LT6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,203,443</td><td style="text-align: left"> </td></tr> </table>

267587

2709261

1226595

4203443

337432

100000

2.246

800000

60257

1087266

2.47

1087266

10000000.0

15000000

7000

10000

500000

39943

1000

39900000

2000000.0

4500

0.001

1000

4500000

200000

4300000

600000

5102

0.001

1000

5100000

1154

1150000

5656

4500

3926263

3.64

2.246

33858

15074610

2.246

SCHEDULE OF OUTSTANDING PREFERRED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Authorized Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Conversion Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Equivalent</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 40%">Series A-2</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zzqTAaUYPBc1" style="width: 11%; text-align: right" title="Preferred stock, shares authorized">7,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zDlYqjS2Ald7" style="width: 11%; text-align: right" title="Preferred stock, shares outstanding">601</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zw3lAHq7vtqi" style="width: 11%; text-align: right" title="Preferred stock, conversion price">2.246</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesA2ConvertiblePreferredStockMember_zdZPL2drFIPj" style="width: 11%; text-align: right" title="Preferred stock, common stock equivalent">267,587</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Series B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--PreferredStockSharesAuthorized_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zqyUyA3sZUO8" style="text-align: right" title="Preferred stock, shares authorized">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PreferredStockSharesOutstanding_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zO4dKv05xC6i" style="text-align: right" title="Preferred stock, shares outstanding">6,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zMUczSjHGiKj" style="text-align: right" title="Preferred stock, conversion price">2.246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20260331__us-gaap--AwardTypeAxis__custom--SeriesBConvertiblePreferredStockMember_zJ0nahX33qk9" style="text-align: right" title="Preferred stock, common stock equivalent">2,709,261</td><td style="text-align: left"> </td></tr> </table>

7000

601

2.246

267587

500000

6085

2.246

2709261

1000

3.64

2.80

2.246

1.82 1.40

1.00

107

<p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7ERFMhi3Jwd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the equity classified compensatory warrant activity for the three months ended March 31, 2026: SCHEDULE OF COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Total outstanding – December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zd3epEQSJPmi" style="width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">160</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zDPwW6ZYuzPk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zLY7lTZmFEaf" title="Range of exercise price - beginning">1,270.25 — $<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zQp224rmLVIh" title="Range of exercise price - beginning">1,270.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMK87dSDOzV8" title="Weighted Average Remaining Life (Years) - outstanding">0.81</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaaea16XhROg" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4X3IuGtbhEe" style="text-align: right" title="Weighted average exercise price per share warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zRsyoOqKkGo5" style="text-align: right" title="Number of Shares, Warrants Expired">(53</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOr3Ewa5lpGk" style="text-align: right" title="Weighted average exercise price per share warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zf9XXYL6jsCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrstNWAIPln5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total outstanding – March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQZRgyvb1Shc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">107</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z8IbwlsQ6vTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zpDRbFcqonn3" title="Range of exercise price - ending">1,270.25— $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_ziRq5FjeRCX5" title="Range of exercise price - ending">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zm80mgfFqdOb" title="Weighted Average Remaining Life (Years) - outstanding">0.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfPkpeWtDTge" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">107</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhJ0Ae88TCcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zfnKS4aiQ9i" title="Range of exercise price, exercisable">1,270.25 — $<span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zUZWsE1cG7Je" title="Range of exercise price, exercisable">1,270.25</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z97LRCaPiAd8" title="Weighted Average Remaining Life (Years) Exercisable">0.90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zym3l0W9GpD5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdrSgNdFz4Ei" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zCH3GX0o6Wd4" title="Range of Exercise Price, Non-Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table>

160

1270.25 1270.25 1270.25 P0Y9M21D

107

1270.25 1270.25 1270.25 P0Y10M24D 107 1270.25 1270.25 1270.25 P0Y10M24D

509

1270.25 1270.25 1270.25 P0Y8M8D

345

1270.25 1270.25 1270.25

164

1265.45 1270.25 1270.25 P1Y6M10D 164 1265.45 1270.25 1270.25 P1Y6M10D

50000

82.50

36.50

31998

18002

36.50

13.00

60017

18001

13.00

6.50

27587

36001

13.00

6.50

13.00

6.50

27587

2314

14997

239456

6.45

0.05

188257

51199

16019

1353

6.50 904

54002

6.50

5.82

1586

1087266

2.47

1087266

<p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zOvdSGkpavdj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2026: SCHEDULE OF NON COMPENSATORY WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Total outstanding – December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUAdpXmByRh8" style="width: 11%; text-align: right" title="Number of shares, warrants outstanding beginning">1,159,270</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVRQuxd6HyNj" style="width: 11%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">2.72</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">$<span id="xdx_903_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zi4Ji2mNFdkb" title="Range of exercise price">2.47 — $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iS_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zlenqPotqzq3" title="Range of exercise price">6.50 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zY3woDGRX4m" title="Weighted average remaining life (Years) exercisable">4.64</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGbh3EGC4np3" style="text-align: right" title="Number of shares, warrants outstanding granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zM8YNv8CxzG2" style="text-align: right" title="Weighted average exercise price, warrants granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGa5eOgDuPbb" title="Range of exercise price warrant, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjdDKECdy2L3" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxJLV0baiSnc" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zty1QU1ZHlT4" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zIXAlCixEEDb" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGKijhPumQib" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zr1M32WZC6Jf" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zhc5D79n6sTg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_ziekdejfEOQh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zy9T71BqIMec" title="Range of Exercise Price, Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Total outstanding – March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0YQkvQI1r55" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">1,159,270</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zHi4o7mz6Zib" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">2.72</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z4S2MC3yPiB3" title="Range of exercise price">2.47 — $<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iE_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqde0sW1oT2l" title="Range of exercise price">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_znFfLd4DpHmj" title="Weighted average remaining life (Years) exercisable">4.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAIZrlNYosnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,159,270</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zkW87GAYknRc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.72</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_907_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z6hiqKVJxnc4" title="Range of exercise price, exercisable">2.47 — $<span id="xdx_905_ecustom--RangeOfExercisePriceExercisableVested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcBEwuZfTowg" title="Range of exercise price, exercisable">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zvsjVEvHBtrk" title="Weighted average remaining life (Years) exercisable">4.39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxTIVOPjLrHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zt1d7Fr8tI29" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20260331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGfHZAgw2ril" title="Range of exercise price, Non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table> The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: transparent"> <td> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of Exercise Price</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted– Average Remaining Life (Years)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Total outstanding – December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zAmw5OWJUENj" style="width: 11%; text-align: right" title="Number of shares, warrants outstanding beginning">72,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6CAlzgig9uh" style="width: 11%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">6.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">$<span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zosh8wRaKZT5" title="Range of exercise price">6.50 — $<span id="xdx_904_ecustom--RangeOfExercisePriceOutstanding_iS_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zMOgXeDLvYw9" title="Range of exercise price">6.50 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zufNVAiJDvri" title="Weighted average remaining life (Years) exercisable">3.99</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zYIAXOuvNvI1" style="text-align: right" title="Number of shares, warrants outstanding granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6WYrcEs7mdi" style="text-align: right" title="Weighted average exercise price, warrants granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--RangeOfExercisePriceExercisableGranted_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyOf5FywJcN5" title="Range of exercise price warrant, granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zRTCmbokoTxc" style="text-align: right" title="Number of Shares, Warrants Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zd8PQdJhNja8" style="text-align: right" title="Weighted average exercise price, warrants exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--RangeOfExercisePriceExercisableExcercised_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zE1WEGjLICQe" title="Range of Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJy0zZT0v2ek" style="text-align: right" title="Number of Shares, Warrants Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zKZS10HN4qx7" style="text-align: right" title="Weighted average exercise price, warrants expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFg05veyQPwl" title="Range of Exercise Price, Expired">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJu9BWPnOVj2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Warrants Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZ3Cd5GSn4Ll" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInRangeOfExercisePrice_iI_pid_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zqANX2GrWhvj" title="Range of Exercise Price, Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Total outstanding – March 31, 2025</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zOVG07JtlyYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">72,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNTcK8by3y86" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">6.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z78zflE97Cic" title="Range of exercise price">6.50 — $<span id="xdx_901_ecustom--RangeOfExercisePriceOutstanding_iE_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zotQnlWPDip2" title="Range of exercise price">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6e5s1lv8aHf" title="Weighted average remaining life (Years) exercisable">3.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZ8wcVs8Xud2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">72,004</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6Rwp2wrfryb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">6.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z3L3BZ0yCbzl" title="Range of exercise price, exercisable">6.50 — $<span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zzLoOuAP1FTk" title="Range of exercise price, exercisable">6.50 </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zmzPh0ugkyt5" title="Weighted average remaining life (Years) exercisable">3.74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zqpVcyVzLja1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zVsy5vxXkgyh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20250331__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zFSTi3C29lgi" title="Range of exercise price, Non-exercisable">—</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="text-align: left"> </td></tr> </table>

1159270

2.72 2.47 6.50 P4Y7M20D

1159270

2.72 2.47 6.50 P4Y4M20D 1159270 2.72 2.47 6.50 P4Y4M20D

72004

6.50 6.50 6.50 P3Y11M26D

72004

6.50 6.50 6.50 P3Y8M26D 72004 6.50 6.50 6.50 P3Y8M26D

<p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zGoooW3PO2W7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 15 — RELATED PARTY TRANSACTIONS Lead Investor Agreement In connection with the Subscription Agreement, the Company and Faraday Future Intelligent Electric Inc. entered into a Lead Investor Agreement. Pursuant to this agreement, Faraday committed to invest a minimum of $30 million in a Private Placement. The material terms of the Lead Investor Agreement include: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Treasury Reserve & Crypto Custody: The Company will adopt a Treasury Reserve Policy establishing cryptocurrencies as its primary ongoing treasury reserve asset.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Executive Appointments: Concurrent with the closing, Faraday appointed Jiawei Wang as Co-Chief Executive Officer and Koti Meka as Chief Financial Officer. The Faraday-appointed Co-CEO is solely responsible for all non-legacy business operations and has been granted sole access to all crypto-related accounts of the Company, subject to delegation.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Board Restructuring: The Board size was initially reduced to five members, with Faraday appointing two initial directors to fill vacancies. Following stockholder approval, the Board will expand to seven members, granting Faraday the right to appoint up to two additional directors. Faraday retains the right to proportional board representation so long as it maintains at least 5% beneficial ownership of the Company’s Common Stock.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Transitional Governance Controls: Prior to receiving stockholder approval, the Faraday-appointed Co-CEO will manage all new business affairs and holds the exclusive authority to approve and execute new agreements on behalf of the Company. Legacy business affairs continue to be managed by the current CEO.</td></tr> </table> Actual proceeds from the Lead Investor Agreement from Faraday as well as several members of Faraday’s executive management team amounted to $<span id="xdx_908_ecustom--ProceedsFromInvestor_pn5n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__us-gaap--ExecutiveCommitteeMember_zwhAvDeYZWy2" title="Proceeds from investor">34.2 million. As part of the Lead Investor Agreement, YT Jia, the Co Chief Executive Officer of Faraday, contributed $<span id="xdx_90F_ecustom--ProceedsFromInvestor_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zC2hwb3S9AK7" title="Proceeds from investor">4,000,000. As part of the Lead Investor Agreement, Jerry Wang, the President of Faraday, contributed $<span id="xdx_90C_ecustom--ProceedsFromInvestor_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--LeadInvestorAgreementMember__srt--TitleOfIndividualAxis__srt--PresidentMember_zR09PJHdDsmb" title="Proceeds from investor">200,000. Master Service Agreement On September 30, 2025 the Company entered into a Transition Services Agreement with Faraday to provide support and management services. During the three months ended March 31, 2026, approximately $<span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember_zwhcXAyTLqXe" title="Transition services charged">0.5 million was charged to the Company under the Transition Services Agreement and fully paid by the end of the period. During the three months ended March 31, 2026, $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn5n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember_zGzdG1f7Wgl2" title="Transition services charged">0.5 million was charged to the Company under the Transition Services Agreement, none of which was outstanding as of year end. There was no expenses charged under this agreement in the three months ended March 31, 2025. The balance of charges dues under this agreement was $<span id="xdx_901_eus-gaap--OtherLiabilitiesCurrent_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHgrsN65y8s6" title="Transition services charged">1.0 million as of December 31, 2025 and was classified under Related Party Payable on the consolidated balance sheet Related Party Accrued Expenses In 2025 the Company entered into verbal agreements with several members of management and consultants, including Faraday Future Global Partners (a company that shares several board members with Faraday), the Chief Executive Officer of Faraday, several board members of Faraday, members of the audit committee of the Company, the Chief Executive Officer of the Company, and the Chief Financial Officer of Faraday, to provide management consulting services. These agreements were finalized in 2026, and were made retroactive to November 1, 2025. The agreements includes services beginning in the year ended December 31, 2025 in the total amount of approximately $639,000. This amount was outstanding as of December 31, 2025 and is classified under Related Party Payable on the unaudited condensed consolidated balance sheet. During the three months ended March 31, 2026, a total amount of approximately $805,000 was charged under these agreements, and as of March 31, 2026 approximately $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FaradayFutureGlobalPartnersMember_zgnqR9or2jp" title="Related party payable">448,000 was outstanding, and was classified under Related Party Payable. Warrants On May 22, 2020, as a commitment fee, the Company issued warrants to Alpha for the purchase of common stock. As of December 31, 2024, 141 of these warrants remained outstanding and exercisable, and were able to be exercised in whole or in part, at any time before May 22, 2025. These warrants expired, and as of December 31, 2025, none of these warrants remain outstanding and exercisable. During years ended December 31, 2025 and 2024 there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8KO0kzBlkii" title="Number of warrant exercised"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_do_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoV2hzEozD9l" title="Number of warrant exercised">no exercises of this warrant. This warrant was equity classified as of December 31, 2023 and was reclassified to warrant liabilities during the year ended December 31, 2024 (see Note 8 - Warrant Liabilities). On December 22, 2022, in conjunction with the issuance of a debenture to Alpha, the Company issued to Alpha a warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zU01BgfufYih" title="Warrant to purchase shares">50,000 shares of the Company’s common stock. This warrant may be exercised by Alpha, in whole or in part, on or after June 22, 2023 and at any time before June 22, 2028, subject to certain terms and conditions described in the warrant. During the year ended December 31, 2024, Alpha partially exercised this warrant to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z1ZpXEsDAjR7" title="Warrant exercised">31,998 shares respectively, of the Company’s common stock at a weighted average exercise price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zBM66VFFdl19" title="Weighted average exercise price">13.00, for total cumulative proceeds to the Company of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zgw0ZtMTbc94" title="Cumulative proceeds from issuance of warrants">416,000. During the year ended December 31, 2025, there were no exercises of this warrant. This warrant is included in equity on the Company’s unaudited condensed consolidated balance sheets (see Note 14 – Stockholders’ Equity ). On February 27, 2024, in conjunction with the issuance of a debenture to Alpha, the Company issued to Alpha, a warrant to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240227__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zqgNWBmtr75i" title="Warrant to purchase shares of common stock">18,001 shares of the Company’s common stock , exercisable in whole or in part, until February 27, 2029, subject to certain terms and conditions described in the warrant. This warrant is presented on the balance sheet as an equity classified warrant. On September 6, 2024 as a result of the down-round provision triggered by shares sold in a public offering, the above warrants were repriced from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240905__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z8nQ63hESyJl" title="Exercise price of warrant">13.00 per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zEZaoTf9Mvn4" title="Exercise price of warrant">6.50 per share exercise price. The company recognized an additional deemed dividend of $27,587, which represents the incremental fair value of the outstanding warrants as a result of the down-round provision. As the Company has an accumulated deficit, the deemed dividend was recorded as a reduction in additional paid-in capital, resulting in a net impact of zero to additional paid-in capital in the unaudited condensed consolidated statements of changes in stockholders’ equity. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor. As a result of a partial voluntary conversion of the 2024 Alpha Debenture on September 9, 2024, the Company no longer had sufficient shares to settle the 2024 Alpha Warrant in full until shareholder approval was obtained, and a portion (2,314 warrant shares with a fair value of $14,997) was reclassified to liabilities (see Note 8 – Warrant Liabilities). Shareholder approval was subsequently obtained on October 25, 2024, and as of that date, the Company determined that shareholder approval resulted in equity classification for the warrant again and, accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants. During the three months ended March 31, 2026, there were no exercises of this warrant. This warrant is included in equity on the Company’s unaudited consolidated balance sheets (see Note 14 – Stockholders’ Equity). As of March 31, 2026, the exercise price of all of the above warrants issued to Alpha was $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zBOQhEKVoTif" title="Exercise price of warrant">6.50. On April 12, 2024, in connection with the issuance of a debenture to Chen (see Note 9 – Convertible Debt), the Company issued a liability classified warrant to Chen to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--YiHuaChenMember_zkWRAYRj61j3" title="Warrant to purchase shares">36,001 shares of common stock, exercisable until February 27, 2029. On September 6, 2024, as a result of a down-round provision triggered by shares sold in a public offering, the warrant was repriced from an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240227__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zE0LgMyY6X0g" title="Exercise price of warrant">13.00 per share to an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240906__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zwa0YYPLXp44" title="Exercise price of warrant">6.50 per share. The warrant was initially liability classified due to an insufficient number of authorized shares to settle the warrant prior to the receipt of shareholder approval, which was subsequently obtained on October 25, 2024. As of that date, the Company determined that shareholder approval resulted in equity classification for the warrant and accordingly, the Company remeasured the warrant liability to fair value, and reclassified to noncompensatory equity classified warrants (see Note 14 – Stockholders’ Equity). The fair value of this warrant was $565,582 on the issuance date and $185,531 on the date of reclassification to equity. On April 28, 2025, as a result of the down-round provision triggered by the issuance of the 2025 Convertible Note, the warrant was repriced from an exercise price of $6.50 per share to an exercise price of $5.82 per share. No further down-round provisions were triggered by the July 28, 2025 private placement transaction or the Subscription Agreement as these warrants were at their contractual floor. Prepaid Investment In February 2026, the Company paid $<span id="xdx_909_eus-gaap--PaymentsToAcquireOtherInvestments_pn5n6_c20260201__20260228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FaradayFutureIntelligentElectricIncMember_zIi2wcsgZiql" title="Prepayment of investments">10.0 million to Faraday, a related party, as part of an entrusted investment arrangement pursuant to which GKA was engaged to acquire equity securities on the Company’s behalf. As of March 31, 2026, the underlying securities had not been issued and the Company had not obtained ownership rights, and the advance is recorded as a prepaid investment as discussed in Note 5 – Prepaid Investment, Prepaid Expenses and Other Current Assets.

30000000

34200000 4000000 200000

500000

1000000.0

639000

805000

448000

50000

31998

13.00

416000

18001

13.00

6.50

27587

6.50

5.82

2314

14997

6.50

36001

13.00

6.50

565582 185531

6.50

5.82

10000000.0

NOTE 16 — SEGMENT INFORMATION The Company operates as a single operating and reportable segment. This determination is consistent with the manner in which the Company’s Chief Operating Decision Maker (“CODM”) evaluates performance, allocates resources, and reviews financial results. The CODM consists of the Company’s two Co-Chief Executive Officers and its Chief Financial Officer. The CODM reviews consolidated financial information and does not receive discrete financial information for separate business components. Prior to the Offering (see Note 1 – Organization and Summary of Significant Accounting Policies and Estimates), the CODM consisted of the sole Chief Executive Officer. In accordance with ASC 280, Segment Reporting, the Company has concluded that it has one operating and reportable segment because its financial results are reviewed on a consolidated basis and no component meets the definition of a separate operating segment. The Company’s operations primarily consist of the development and commercialization of AI-enabled technology products and services, including AI-based trading tools, digital-asset tokenization and embedded AI services, and AI-powered cryptocurrency portfolio management solutions. Prior to the Offering, the Company was an early-stage clinical therapeutics company focused on developing treatments for adult and pediatric cancer. The CODM evaluates performance and allocates resources based on consolidated net income (loss). The CODM reviews the Company’s significant segment expenses, which are its consolidated operating expenses, including research and development, general and administrative, and interest and other expenses, broken out as follows: <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zI5Qo57cbfle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zzkE3m1UMcU1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20250101__20250331__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zEkwUnMFWZZ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zYxhqYcWU55j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">EXPENSES</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz3SZ_zI8e0v1aZG98" style="vertical-align: bottom"> <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,547,853</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,494,532</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_i01_maOEz3SZ_zKCB5UyT9qha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Sales and Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">638,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz3SZ_zaSfVotywiB7" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,072</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--CreditLossExpenseShorttermNoteReceivable_i01_maOEz3SZ_z6MLtMZXy4i4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Credit loss expense - short-term note receivable</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">142,574</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">197,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtOEz3SZ_msNILzv6O_zdwd8JCsyzob" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Total expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,333,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,724,699</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_iN_di_maNILzv6O_z2nR68HxEps7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total other expense (income), net (1)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,745,295</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(78,527</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iNT_di_mtNILzv6O_zi1Dd4ZDTUCf" style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">NET LOSS</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,079,016</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,646,172</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes total non-operating expenses and provision for income taxes.</td></tr> </table> The CODM evaluates the Company’s financial position based on the consolidated balance sheet and does not review segment-level asset information. Accordingly, no separate segment asset disclosures are presented.

<p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zI5Qo57cbfle" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_492_20260101__20260331__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zzkE3m1UMcU1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20250101__20250331__us-gaap--AwardTypeAxis__custom--SegmentReportingExpenseInformationMember_zEkwUnMFWZZ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zYxhqYcWU55j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">EXPENSES</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz3SZ_zI8e0v1aZG98" style="vertical-align: bottom"> <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,547,853</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,494,532</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_i01_maOEz3SZ_zKCB5UyT9qha" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Sales and Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">638,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz3SZ_zaSfVotywiB7" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,072</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,167</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--CreditLossExpenseShorttermNoteReceivable_i01_maOEz3SZ_z6MLtMZXy4i4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Credit loss expense - short-term note receivable</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">142,574</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">197,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtOEz3SZ_msNILzv6O_zdwd8JCsyzob" style="vertical-align: bottom"> <td style="padding-left: 10pt; text-align: left">Total expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,333,721</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,724,699</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpense_iN_di_maNILzv6O_z2nR68HxEps7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total other expense (income), net (1)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,745,295</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(78,527</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iNT_di_mtNILzv6O_zi1Dd4ZDTUCf" style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">NET LOSS</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,079,016</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,646,172</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes total non-operating expenses and provision for income taxes.</td></tr> </table>

3547853

2494532

638222

5072

33167

142574 197000

4333721

2724699

-1745295

78527

-6079016

-2646172

NOTE 17 — SUBSEQUENT EVENTS On April 10, 2026, the Company entered into first and second amendments to its previously disclosed entrusted investment agreement with GKA and Song Wang, which expanded the scope of entrusted assets to include preferred equity and debt instruments of Faraday and modified certain governance and option provisions. On April 14, 2026, GKA and Faraday executed an amended and restated securities purchase agreement increasing the aggregate investment to $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20260414__20260414__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zjnB7avKzpk6" title="Proceeds from issuance of common stock">12.0 million, consisting of purchases of Faraday Class A common stock and newly designated Series C Convertible Preferred Stock. The amended agreement eliminated prior price protection provisions in exchange for the issuance of a warrant exercisable for <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260414__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zW6coP4L6Euk" title="Warrant exercisable">1,000,000 shares of Faraday Class A common stock, subject to customary ownership limitations and Nasdaq requirements. The transaction closed on April 15, 2026, upon which the subject securities were issued. In connection with the transaction, GKA provided a $2.0 million unsecured loan to Faraday on April 10, 2026, funded by the Company under the entrusted investment agreement. Upon execution of the amended and restated securities purchase agreement on April 14, 2026, all outstanding principal and accrued interest under the loan were canceled and extinguished and the loan agreement was terminated. As these agreements were executed after the balance sheet date and do not provide evidence of conditions existing as of that date, they represent non-recognized subsequent events under ASC 855, and no adjustments have been made to the Company’s unaudited condensed consolidated financial statements. On April 17, 2026, the Company filed a Registration Statement on Form S-8 to register an aggregate of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKUKU2Blqozh" title="Common stock shares reserved for future issuance">1,047,865 shares of the Company’s common stock, par value $0.001 per share, reserved and available for issuance pursuant to the Company’s 2025 Equity Incentive Plan.

12000000.0

1000000

2000000.0

1047865

0.001

false false false false Additions represent purchases of crypto assets held for investment, dispositions represent liquidation of crypto assets held for investment The Company measures gains and losses by each asset held. These amounts include cumulative unrealized gains of $364,027, realized losses of $398,720, and unrealized losses of $1,910,889 during the three months ended March 31, 2026 excludes 51,199 pre-funded warrants which have no expiration date excludes 51,199 pre-funded warrants which have no expiration date. Includes total non-operating expenses and provision for income taxes.